"Source","Contributors","Variable","Level","CellTissue","Complex","IndividualLevelData","DataCapture","Entrez","GO","GOManual","CHEBI","MPO","MPOLabel","Description","Value","Meta","VarWithinD","VarDvsCTRL","Relevance","Range","Recode","Method","MethodDetails","Type","PrivateNote","Note","DataSource","DataSourceLink"
"PMID29415062","Simeonovic et al. (2018)","HS","protein","islet of Langerhans",0,"Yes",1,"NA","NA","NA","CHEBI:28815","MP:0013258","abnormal extracellular matrix morphology","Expression of heparan sulfate","mean % islet area stained","HSPG core proteins","NA","1","Significantly higher in T1D","0-100","no","immunostaining","IHC image to % islet area stained was quantified using ImageJ.","interval",,"Mean % was manually calculated from multiple stains per case from the raw data in the supplemental files.","S1 Table: Percentage of islet area stained for HS, HSPGs (Col18 and Sdc1), insulin and glucagon in normal healthy and T1D human pancreases.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802856/bin/pone.0191360.s006.xlsx"
"PMID29415062","Simeonovic et al. (2018)","Col18","protein","islet of Langerhans",0,"Yes",1,"80781","NA","NA",,"MP:0013258","abnormal extracellular matrix morphology","Expression on collagen type XVIII","mean % islet area stained","HSPG core proteins","NA","1","Significantly higher in T1D","0-100","no","immunostaining","IHC image to % islet area stained was quantified using ImageJ.","interval",,"Mean % was manually calculated from multiple stains per case from the raw data in the supplemental files.","S1 Table: Percentage of islet area stained for HS, HSPGs (Col18 and Sdc1), insulin and glucagon in normal healthy and T1D human pancreases.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802856/bin/pone.0191360.s006.xlsx"
"PMID29415062","Simeonovic et al. (2018)","Sdc1","protein","islet of Langerhans",0,"Yes",1,"6382","NA","NA",,"MP:0013258","abnormal extracellular matrix morphology","Expression of syndecan-1","mean % islet area stained","HSPG core proteins","NA","1","Significantly higher in T1D","0-100","no","immunostaining","IHC image to % islet area stained was quantified using ImageJ.","interval",,"Mean % was manually calculated from multiple stains per case from the raw data in the supplemental files.","S1 Table: Percentage of islet area stained for HS, HSPGs (Col18 and Sdc1), insulin and glucagon in normal healthy and T1D human pancreases.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802856/bin/pone.0191360.s006.xlsx"
"PMID29415062","Simeonovic et al. (2018)","Ins","protein","islet of Langerhans",0,"Yes",1,"NA","NA","NA",,"MP:0020578","abnormal pancreatic beta cell number","Expression of insulin","mean % islet area stained","HSPG core proteins","NA","1","Significantly lower in T1D","0-100","no","immunostaining","IHC image to % islet area stained was quantified using ImageJ.","interval",,"Mean % was manually calculated from multiple stains per case from the raw data in the supplemental files.","S1 Table: Percentage of islet area stained for HS, HSPGs (Col18 and Sdc1), insulin and glucagon in normal healthy and T1D human pancreases.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802856/bin/pone.0191360.s006.xlsx"
"PMID29415062","Simeonovic et al. (2018)","Gcg","protein","islet of Langerhans",0,"Yes",1,"NA","NA","NA",,"MP:0020577","abnormal pancreatic alpha cell number","Expression of glucagon","mean % islet area stained","HSPG core proteins","NA","1","Significantly higher in T1D","0-100","no","immunostaining","IHC image to % islet area stained was quantified using ImageJ.","interval",,"Mean % was manually calculated from multiple stains per case from the raw data in the supplemental files.","S1 Table: Percentage of islet area stained for HS, HSPGs (Col18 and Sdc1), insulin and glucagon in normal healthy and T1D human pancreases.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802856/bin/pone.0191360.s006.xlsx"
"PMID29352311","Bonnet-Serrano et al. (2018)","alpha.mass","cell","pancreatic A cell",0,"Pending authorization",1,"NA","NA","NA",,"MP:0030587","abnormal pancreatic alpha cell mass","Mass of alpha cells",,,,,,,,,,,,,,"NA"
"PMID29352311","Bonnet-Serrano et al. (2018)","beta.mass","cell","type B pancreatic cell",0,"Pending authorization",1,"NA","NA","NA",,"MP:0009112","abnormal pancreatic beta cell mass","Mass of beta cells",,,,,,,,,,,,,,"NA"
"PMID29222447","Bogdani et al. (2017)","Ki67.Ins.cells","cell","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,"MP:0011818","abnormal pancreatic beta cell proliferation","Beta-cell proliferation","% Ki67+/Ins+ cells",,"NA","NA",,"0-100","no","immunostaining",,"interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722914/figure/Fig3/"
"PMID29222447","Bogdani et al. (2017)","CK19.Ins.cells","cell","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,"MP:0011818","abnormal pancreatic beta cell proliferation","Beta-cell neogenesis","% CK19+/Ins+ cells",,"NA","NA",,"0-100","no","immunostaining",,"interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722914/figure/Fig3/"
"PMID29222447","Bogdani et al. (2017)","CF.grade","cell","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Cystic fibrosis histopathologic grade based on staining","grade",,"NA","NA",,"N(ormal),1-5","no","immunostaining",,"ordinal",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722914/figure/Fig2/"
"PMID29222447","Bogdani et al. (2017)","Ins","protein","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Percent of insulin-positive cells in islet","% Ins+ cells",,"NA","NA",,"0-100","no","immunostaining",,"interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722914/figure/Fig2/"
"PMID29222447","Bogdani et al. (2017)","Synaptophysin","protein","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Relative pancreas synaptophysin area stained","% Syn+ area stained",,"NA","NA",,"0-100","no","immunostaining",,"interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722914/figure/Fig2/"
"PMID29222447","Bogdani et al. (2017)","CFTR.mut","genotype",,1,"Contact authors",0,"NA","NA","NA",,,,"Genotyping for 159 CFTR variants","Positive/Negative",,"NA","NA",,"0-159","no","MALDI-TOF",,"interval",,,,"NA"
"PMID29128936","Kusmartseva et al. (2017)","hosp.bin","clinical",,0,"Yes",1,"NA","NA","NA",,,,"hospitalisation time, binned",,,,,,,,,,,,,,"https://doi.org/10.5281/zenodo.1034422"
"PMID29128936","Kusmartseva et al. (2017)","Ki67.cells","cell","islet of Langerhans",0,"Yes",1,"NA","NA","NA",,"MP:0005518","abnormal pancreas regeneration","Mean Ki67+ cells as percentage of total islet cells counted","%",,,,,,,"immunostaining",,,,,,"https://doi.org/10.5281/zenodo.1034422"
"PMID29128936","Kusmartseva et al. (2017)","Ki67.Ins.cells","cell","islet of Langerhans",0,"Yes",1,"NA","NA","NA",,"MP:0011818","abnormal pancreatic beta cell proliferation","Mean Ki67+/ins+ cells as percentage of total islet cells counted","%",,,,,,,"immunostaining",,,,,,"https://doi.org/10.5281/zenodo.1034422"
"PMID29128936","Kusmartseva et al. (2017)","CD45.cells","cell","islet of Langerhans",0,"Yes",1,"NA","NA","NA",,"MP:0004031","insulitis","Mean CD45+ cells as percentage of total islet cells counted","%",,,,,,,"immunostaining",,,,,,"https://doi.org/10.5281/zenodo.1034422"
"PMID29128936","Kusmartseva et al. (2017)","CD68.cells","cell","islet of Langerhans",0,"Yes",1,"NA","NA","NA",,,,"Mean CD68+ cells as percentage of total islet cells counted","%",,,,,,,"immunostaining",,,,,,"NA"
"PMID28878130","Levet et al. (2017)","Env03","protein","pancreas",0,"Pending authorization",0,"NA","NA","NA",,,,"HERV-W-Env protein expression in pancreas as percent positive area of total pancreatic tissue area","% positive staining area","Viral","1","1",,"0-100",,"immunostaining","HERV-W-Env expression was assessed on pancreas slices from controls (n = 19) and T1D (n = 20) stained using GN_mAb_Env03 and automatically quantified.",,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621895/figure/F1/"
"PMID28878130","Levet et al. (2017)","CD3.cells.islet.prct","cell","islet of Langerhans",0,"Pending authorization",1,"NA","NA","NA",,,,"CD3+ cells as percent of total cells counted in islet",,,,,,,,,,,,,,
"PMID28878130","Levet et al. (2017)","CD3.cells.islet","cell","islet of Langerhans",0,"Pending authorization",1,"NA","NA","NA",,,,"Mean CD3+ cells in islet per mm^2",,,,,,,,,,,,,,
"PMID28878130","Levet et al. (2017)","CD68.cells.islet.prct","cell","islet of Langerhans",0,"Pending authorization",1,"NA","NA","NA",,,,"CD68+ cells as percent of total cells counted in islet",,,,,,,,,,,,,,
"PMID28878130","Levet et al. (2017)","CD68.cells.islet","cell","islet of Langerhans",0,"Pending authorization",1,"NA","NA","NA",,,,"Mean CD68+ cells in islet per mm^2",,,,,,,,,,,,,,
"PMID28878130","Levet et al. (2017)","CD3.cells.exocrine.prct","cell","exocrine pancreas",0,"Pending authorization",1,"NA","NA","NA",,,,"CD3+ cells as percent of total cells counted in exocrine pancreas",,,,,,,,,,,,,,
"PMID28878130","Levet et al. (2017)","CD3.cells.exocrine","cell","exocrine pancreas",0,"Pending authorization",1,"NA","NA","NA",,,,"Mean CD3+ cells in exocrine pancreas per mm^2",,,,,,,,,,,,,,
"PMID28878130","Levet et al. (2017)","CD68.cells.exocrine.prct","cell","exocrine pancreas",0,"Pending authorization",1,"NA","NA","NA",,,,"CD68+ cells as percent of total cells counted in exocrine pancreas",,,,,,,,,,,,,,
"PMID28878130","Levet et al. (2017)","CD68.cells.exocrine","cell","exocrine pancreas",0,"Pending authorization",1,"NA","NA","NA",,,,"Mean CD68+ cells in exocrine pancreas per mm^2",,,,,,,,,,,,,,
"PMID28877460","Wasserfall et al. (2017)","Ins","protein","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Insulin ELISA normalized against total protein","pM/Protein (microgram/mL)",,"1","1",,"NA","no","ELISA","Acid-ethanol extraction of protein from randomly localized pancreatic blocks, determined and normalized against total protein.","interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc2.xlsx"
"PMID28877460","Wasserfall et al. (2017)","Proins","protein","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Proinsulin ELISA normalized against total protein","pM/Protein (microgram/mL)",,"1","1",,"NA","no","ELISA","Acid-ethanol extraction of protein from randomly localized pancreatic blocks, determined and normalized against total protein.","interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc2.xlsx"
"PMID28877460","Wasserfall et al. (2017)","Cpep","protein","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"C-peptide ELISA normalized against total protein","pM/Protein (microgram/mL)",,"1","1",,"NA","no","ELISA","Acid-ethanol extraction of protein from randomly localized pancreatic blocks, determined and normalized against total protein.","interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc2.xlsx"
"PMID28877460","Wasserfall et al. (2017)","Iapp","protein","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Islet amyloid polypeptide ELISA normalized against total protein","pM/Protein (microgram/mL)",,"1","1",,"NA","no","ELISA","Acid-ethanol extraction of protein from randomly localized pancreatic blocks, determined and normalized against total protein.","interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc2.xlsx"
"PMID28877460","Wasserfall et al. (2017)","Gcg","protein","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Glucagon ELISA normalized against total protein","pM/Protein (microgram/mL)",,"0","0",,"NA","no","ELISA","Acid-ethanol extraction of protein from randomly localized pancreatic blocks, determined and normalized against total protein.","interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc2.xlsx"
"PMID28877460","Wasserfall et al. (2017)","Ins.cells","cell","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Insulin+ single cells","count",,"1","1",,"NA","no","immunostaining",,"NA",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc2.xlsx"
"PMID28877460","Wasserfall et al. (2017)","Ins.Ggc.cells","cell","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Glucagon+Insulin+ islets and Glucagon+Insulin- islets","count",,"1","1",,"NA","no","immunostaining",,,,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc2.xlsx"
"PMID28877460","Wasserfall et al. (2017)","INS","transcript","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Insulin mRNA determined by situ hybridization","NA",,"1","1",,"NA","no","immunostaining",,,,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc2.xlsx"
"PMID28877460","Wasserfall et al. (2017)","INS.2","transcript","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Insulin mRNA","Cq",,"1","1","Low, but reproducible, levels of INS mRNA in T1D pancreata (lower than controls)","NA","no","qPCR",,"interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc2.xlsx"
"PMID28877460","Wasserfall et al. (2017)","INS.hnRNA","transcript","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Insulin heterogeneous nuclear RNA","Cq",,"1","1","Very little, if any, de novo synthesis of INS hnRNA, indicating that the INS promoter was essentially silent in T1D pancreata","NA","no","qPCR",,"interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc2.xlsx"
"PMID28877460","Wasserfall et al. (2017)","INS.IGF2","transcript","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"INS-IGF2 mRNA","Cq",,"1","1","No detectable mRNA indicates an inactive INS promoter since","NA","no","qPCR",,"interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc2.xlsx"
"PMID28877460","Wasserfall et al. (2017)","IAPP","transcript","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"islet amyloid polypeptide mRNA","Cq",,"1","1","IAPP mRNA levels were substantially lower in T1D","NA","no","qPCR",,"interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc2.xlsx"
"PMID28877460","Wasserfall et al. (2017)","Gcg","transcript","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Glucagon mRNA","Cq",,"0","0","Similar levels in T1D and controls.","NA","no","qPCR",,"interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc2.xlsx"
"PMID28877460","Wasserfall et al. (2017)","SST","transcript","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Somatostatin mRNA","Cq",,"0","0","Similar levels in T1D and controls.","NA","no","qPCR",,"interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc2.xlsx"
"PMID28877460","Wasserfall et al. (2017)","PCSK1","transcript","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"prohormone convertase 1 mRNA","Cq",,"1","1","mRNA expression was reduced among T1D pancreata compared to controls","NA","no","qPCR",,"interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc2.xlsx"
"PMID28877460","Wasserfall et al. (2017)","PCSK2","transcript","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"prohormone convertase 2 mRNA","Cq",,"0","0","Similar levels in T1D and controls.","NA","no","qPCR",,"interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc2.xlsx"
"PMID28877460","Wasserfall et al. (2017)","CPE","transcript","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"carboxypetidase E mRNA","Cq",,"0","0","Similar levels in T1D and controls.","NA","no","qPCR",,"interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc2.xlsx"
"PMID28877460","Wasserfall et al. (2017)","IFNg","transcript","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"IFNgamma mRNA","Cq",,"NA","0","Undetectable in both T1D and controls","NA","no","qPCR",,"interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc1.pdf"
"PMID28877460","Wasserfall et al. (2017)","IL1b","transcript","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"IL1beta mRNA","Cq",,"NA","0","Similar levels in T1D and controls.","NA","no","qPCR",,"interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc1.pdf"
"PMID28877460","Wasserfall et al. (2017)","TNFa","transcript","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"TNFalpha mRNA","Cq",,"NA","0","Undetectable in approximately 30% of T1D and 50% of control samples","NA","no","qPCR",,"interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc1.pdf"
"PMID28877460","Wasserfall et al. (2017)","CALM1","transcript","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"CALM1 heterogeneous nuclear RNA","Cq",,"0","0","Similar levels in T1D and controls","NA","no","qPCR",,"interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc1.pdf"
"PMID28877460","Wasserfall et al. (2017)","SPINK1","transcript","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"SPINK1 heterogeneous nuclear RNA","Cq",,"0","0","Similar levels in T1D and controls","NA","no","qPCR",,"interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc1.pdf"
"PMID28877460","Wasserfall et al. (2017)","PPIA","transcript","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"PPIA heterogeneous nuclear RNA","Cq",,"0","0","Similar levels in T1D and controls","NA","no","qPCR",,"interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117304989-mmc1.pdf"
"PMID28877242","Nyalwidhe et al. (2017)","Proteomics","protein","islet of Langerhans",1,"Yes",1,"NA","NA","NA",,,,"Proteomics of islet tissue, expression data for ~1500 proteins ","LFQ intensity",,"NA","1",,"NA","no","LC/MS","High resolution high mass accuracy label free quantitative mass spectrometry analysis was applied to islets isolated by laser capture microdissection.","interval",,,"S4 Table: Qualitative and quantitative comparisons between non-diabetes versus autoantibody cases and T1D cases.   ","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587329/bin/pone.0183908.s006.xlsx"
"PMID28782056","Moin et al. (2017)","CgA.cells","protein","pancreatic endocrine cell",0,"Contact authors",0,"NA","NA","NA",,,,"Presence and frequency of CPHN cells identified by anti-chromogranin A staining (%CPHN of endocrine cells)","%",,"1* freq differs in adult but not children","0",,"0-100","no","immunostaining",,"interval",,,,"NA"
"PMID28782056","Moin et al. (2017)","Ki67.CgA.cells","protein","pancreatic endocrine cell",0,"Contact authors",0,"NA","NA","NA",,,,"Frequency of replicating CPHN cells identified with Ki67+ staining","%",,"1* freq differs in adult but not children","0",,"0-100","no","immunostaining",,"interval",,,,"NA"
"PMID28782056","Moin et al. (2017)","Nkx61.CgA.cells","protein","pancreatic endocrine cell",0,"Contact authors",0,"NA","NA","NA",,,,"Frequency of replicating CPHN cells identified with endocrine markers by Nkx6.1+ staining and reported as % of CPHN cells","%",,"1* freq differs in adult but not children","0",,"0-100","no","immunostaining",,"interval",,,,"NA"
"PMID28782056","Moin et al. (2017)","Nkx22.CgA.cells","protein","pancreatic endocrine cell",0,"Contact authors",0,"NA","NA","NA",,,,"Frequency of replicating CPHN cells identified with endocrine markers by Nkx2.2+ staining and reported as % of CPHN cells","%",,"1* freq differs in adult but not children","0",,"0-100","no","immunostaining",,"interval",,,,"NA"
"PMID28761107","Sebastiani et al. (2017)","miRs.Treg.PLN","RNA","regulatory T cell_pancreatic lymph node",1,"Contact authors",0,"NA","NA","NA",,,,"microRNA expression of Tregs from pancreatic lymph node (384 miRs measured)","dCT","miRNA","NA","1",,"NA","no","qPCR","Cycles to Threshold (Ct) of PCR and Ct are normalized (dCt) using small RNAs endogenous controls (RNU6A, RNU48, RNU44).","interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537269/figure/Fig1/"
"PMID28761107","Sebastiani et al. (2017)","miRs.Treg.PB","RNA","regulatory T cell_blood",1,"Contact authors",0,"NA","NA","NA",,,,"microRNA expression of Tregs from peripheral blood (384 miRs measured)","dCT","miRNA","NA","1",,"NA","no","qPCR","Cycles to Threshold (Ct) of PCR and Ct are normalized (dCt) using small RNAs endogenous controls (RNU6A, RNU48, RNU44)","interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537269/figure/Fig1/"
"PMID28761107","Sebastiani et al. (2017)","miR125.Treg.PB","RNA","regulatory T cell_blood",0,"Contact authors",0,"NA","NA","NA",,,,"miR-125a-5p relative expression measured by real time-PCR in Treg cells purified from peripheral blood","2^-dCT","miRNA","NA","1",,"NA","no","qPCR","2^-delta cycle threshold (2-dCT) values normalized using three different small RNAs (RNU6, RNU44, RNU48).","interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537269/figure/Fig2/"
"PMID28761107","Sebastiani et al. (2017)","miR125.Treg.PLN","RNA","regulatory T cell_pancreatic lymph node",0,"Contact authors",0,"NA","NA","NA",,,,"miR-125a-5p relative expression measured by real time-PCR in Treg cells purified from pancreatic lymph node","2^-dCT","miRNA","NA","1",,"NA","no","qPCR","2^-delta cycle threshold (2-dCT) values normalized using three different small RNAs (RNU6, RNU44, RNU48).","interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537269/figure/Fig2/"
"PMID28761107","Sebastiani et al. (2017)","miR125.Tconv.PB","RNA","helper T cell_blood",0,"Contact authors",0,"NA","NA","NA",,,,"miR-125a-5p relative expression measured by real time-PCR in Tconv cells purified from peripheral blood","2^-dCT","miRNA","NA","1",,"NA","no","qPCR","2^-delta cycle threshold (2-dCT) values normalized using three different small RNAs (RNU6, RNU44, RNU48).","interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537269/figure/Fig2/"
"PMID28761107","Sebastiani et al. (2017)","miR125.Tconv.PLN","RNA","helper T cell_pancreatic lymph node",0,"Contact authors",0,"NA","NA","NA",,,,"miR-125a-5p relative expression measured by real time-PCR in Tconv cells purified from pancreatic lymph node","2^-dCT","miRNA","NA","1",,"NA","no","qPCR","2^-delta cycle threshold (2-dCT) values normalized using three different small RNAs (RNU6, RNU44, RNU48).","interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537269/figure/Fig2/"
"PMID28761107","Sebastiani et al. (2017)","CCL2.Ins","protein","type B pancreatic cell",0,"Contact authors",0,"NA","NA","NA",,,,"Colocalization analysis between CCL2/Insulin by staining","% colocalization rate",,,,,,,,,"interval","CCL2 is primarily expressed by insulin-producing cells in pancreatic islets and and might serve as potential attractant of CCR2-expressing cells.",,,
"PMID28761107","Sebastiani et al. (2017)","CCL2.Gcg","protein","pancreatic A cell",0,"Contact authors",0,"NA","NA","NA",,,,"Colocalization analysis between CCL2/Glucagon by staining","% colocalization rate",,,,,,,,,"interval",,,,
"PMID28742858","Thivolet et al. (2017)","Ip3r2","protein","type B pancreatic cell",0,"Yes",1,"3709","NA","NA",,,,"Expression of IP3R2 (as mean fluorescence intensity) in beta cells","pixels/islet","mitochondria","NA","1",,"NA","NA","immunofluorescence",,"interval",,,"Table 2: Mean intensity levels in beta cells of IP3R2, TOM20, MFN-2 and VDAC-1 by indirect immunofluorescence and levels of ER-mitochondrial IP3R2-VDAC1 interactions quantified by in situ proximity ligation assay (PA).","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526536/table/pone.0182027.t002/"
"PMID28742858","Thivolet et al. (2017)","Tom20","protein","type B pancreatic cell",0,"Yes",1,"9804","NA","NA",,,,"Expression of TOM20 (as mean fluorescence intensity) in beta cells","pixels/islet","mitochondria","NA","1",,"NA","NA","immunofluorescence",,"interval",,,"Table 2: Mean intensity levels in beta cells of IP3R2, TOM20, MFN-2 and VDAC-1 by indirect immunofluorescence and levels of ER-mitochondrial IP3R2-VDAC1 interactions quantified by in situ proximity ligation assay (PA).","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526536/table/pone.0182027.t002/"
"PMID28742858","Thivolet et al. (2017)","Mfn2","protein","type B pancreatic cell",0,"Yes",1,"9927","NA","NA",,,,"Expression of MFN-2 (as mean fluorescence intensity) in beta cells","pixels/islet","mitochondria","NA","1",,"NA","NA","immunofluorescence",,"interval",,,"Table 2: Mean intensity levels in beta cells of IP3R2, TOM20, MFN-2 and VDAC-1 by indirect immunofluorescence and levels of ER-mitochondrial IP3R2-VDAC1 interactions quantified by in situ proximity ligation assay (PA).","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526536/table/pone.0182027.t002/"
"PMID28742858","Thivolet et al. (2017)","Vdac1","protein","type B pancreatic cell",0,"Yes",1,"7416","NA","NA",,,,"Expression of VDAC-1 (as mean fluorescence intensity) in beta cells","pixels/islet","mitochondria","NA","1",,"NA","NA","immunofluorescence",,"interval",,,"Table 2: Mean intensity levels in beta cells of IP3R2, TOM20, MFN-2 and VDAC-1 by indirect immunofluorescence and levels of ER-mitochondrial IP3R2-VDAC1 interactions quantified by in situ proximity ligation assay (PA).","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526536/table/pone.0182027.t002/"
"PMID28742858","Thivolet et al. (2017)","Ip3r2.Vdac1","protein","type B pancreatic cell",0,"Yes",1,"NA","NA","NA",,,,"Levels of ER-mitochondrial IP3R2-VDAC1 interactions (quantified by in situ proximity ligation) in beta cells","dots/nucleus","mitochondria","NA","1",,"NA","NA","in situ proximity ligation assay (PLA)","Duolink II in situ proximity ligation assay (PLA) (Olink Bioscience, Uppsala Sweden) enables  detection, visualization, and quantification of protein interactions (<40 nm) as an individual dot by microscopy. Dots were quantified in each islet using the Zen program and Fiji-ImageJ software and expressed as percentage of dots per nucleus. Each dot corresponds to one VDAC-1-IP3R2 interaction closer than 40nm.","interval",,,"Table 2: Mean intensity levels in beta cells of IP3R2, TOM20, MFN-2 and VDAC-1 by indirect immunofluorescence and levels of ER-mitochondrial IP3R2-VDAC1 interactions quantified by in situ proximity ligation assay (PA).","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526536/table/pone.0182027.t002/"
"PMID28679961","Schludi et al. (2017)","panIN","cell","pancreas",,,,,,,,,,"Pancreatic Intraepithelial Neoplasia lesions scored for density by group-blinded visual evaluation of stained sections","PanIN lesions/(mm^2 tissue*10^3)",,,"1","PanIN is increased and correlated with higher pancreatic duct gland proliferation in T2D vs controls",,,,"To identify and score the PanIN lesion density, 6 pancreatic sections were evaluated per case by an experienced pancreatic pathologist (DD) blinded to the group. Two sections were evaluated from the head, body, and tail of the pancreas from each case, one of which was stained with Alcian blue and for insulin and Ki67, and the other by H&E.",,,,,
"PMID28679961","Schludi et al. (2017)","density.PDG","cell","pancreas exocrine glandular cell",0,"Contact authors",0,"NA","NA","NA",,,,"Pancreatic duct gland density characterized by group-blinded visual evaluation of stained sections","PDG cells/mm^2",,,0,"PDGs in human pancreas are present in the head, body, and tail with a comparable abundance in individuals with T2DM and ND controls",,,,,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499368/figure/F2/"
"PMID28679961","Schludi et al. (2017)","replication.PDG","cell","pancreas exocrine glandular cell",0,"Contact authors",0,"NA","NA","NA",,,,"Pancreatic duct gland replication characterized by staining for Ki67+ PDGs","Ki67+ PDG cells/mm^2",,,1,"PDG replication was increased 2-fold in T2D vs controls and associated with increased pancreatic intraepithelial neoplasia",,,,,,,,,"NA"
"PMID28679961","Schludi et al. (2017)","replication.interduct","cell","pancreatic ductal cell",0,"Contact authors",0,"NA","NA","NA",,,,"Interlobular duct cell replication characterized by staining for Ki67+ duct cells","Ki67+ interlobular duct cells/mm^2",,,1,"Frequency of interlobular duct cells is increased in T2DM vs controls",,,,,,,,,"NA"
"PMID28679961","Schludi et al. (2017)","replication.intraduct","cell","pancreatic ductal cell",0,"Contact authors",0,"NA","NA","NA",,,,"Intralobular duct cell replication characterized by staining for Ki67+ duct cells","Ki67+ intralobular duct cells/mm^2",,,0,"No difference between T2D vs controls in replication of intralobular duct cells",,,,,,,,,
"PMID28614797","Rodnoi et al. (2017)","Npy","protein","type B pancreatic cell",0,"Contact authors",0,"NA","NA","NA",,,,"NPY expression in beta cells/pancreatic tissue characterized by staining",,"beta cell dedifferentiation","NA","1","NPY expression likely promotes replication and contributes to impaired glucose responsiveness in neonatal beta cells; NPY is reexpressed in a subset of beta cells in both T1D and T2D and correlated with greater residual beta cells",,"no","immunostaining",,"NA",,,"Supplemental Figure 7","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470892/bin/jciinsight-2-94005-s001.pdf"
"PMID28581443","Waqas et al. (2017)","NPFF","transcript","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"NPFF gene expression profiling in islet tissue ","Relative expression",,"NA","1","Relative transcription of NPFF was reduced in pancreatic islets of T1DM patients","NA",,"Affymetrix expression array",,,"All islets in 2–5 sections of tissue from each nPOD donor were laser-captured, pooled and RNA extracted. Samples with sufficient quantity and quality of RNA were then subjected to gene expression analysis using Affymetrix expression arrays.",,"Supplemental Figure 6(H): Distribution of NPFF in mouse and human pancreatic islets","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490745/bin/jci-127-90152-s001.pdf"
"PMID28428323","Jackson et al. (2017)","CD3.cells","cell","islet of Langerhans",0,"Yes",1,"NA","NA","NA",,,,"Insulitis measured as mean CD3+ cells per infiltrated islet","count",,,,,,,,,,,,,
"PMID28428323","Jackson et al. (2017)","beta.mass","cell","type B pancreatic cell",0,"Yes",1,"NA","NA","NA",,,,"Beta cell mass","g",,,,,,,,,,,,,
"PMID28380380","van der Meulen et al. (2017)","Ucn3","protein","type B pancreatic cell",0,"Contact authors",0,"114131","NA","NA",,,,"Expression of Urocortin3 (UCN3) in beta cells (stained images only)",,"beta cell transdifferentation","NA","NA","Ucn3-negative beta cells are virgin beta cells that represent an intermediate stage in the transdifferentiation of alpha cells into mature beta cells","NA","no","immunostaining",,"NA",,,"Figure 5. UCN3-Negative Beta Cells Are Present in Human Islets of Young and Adult Donors and Donors with T1D","https://www.sciencedirect.com/science/article/pii/S1550413117301699?via%3Dihub#fig5"
"PMID28380379","Aguayo-Mazzucato et al. (2017)","Igfr1","protein","type B pancreatic cell",0,"Contact authors",0,"NA","NA","NA",,,,"IGFR1 expression as staining intensity (scale 0-3)",,"aging","1","1",,"0-3","no","immunostaining",,"ordinal",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117301675-mmc1.pdf"
"PMID28380379","Aguayo-Mazzucato et al. (2017)","P53bp1","protein","type B pancreatic cell",0,"Contact authors",0,"7158","NA","NA",,,,"P53BP1 expression as staining intensity",,"aging","1","0",,,"no","immunostaining",,"interval",,,,"https://ars.els-cdn.com/content/image/1-s2.0-S1550413117301675-mmc1.pdf"
"PMID28325643","Anquetil et al. (2017)","IL1b","transcript","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"IL1beta mRNA expression measured by in situ hyridization and reported as percentage of the positive area within the islet boundary","%",,"0","0"," IL-1beta mRNA expression is independent of BMI and disease status","0-100","no","ISH","mRNA expression was quantified with RNAscope 2.0 High Definition BROWN Assay.","interval",,,,"NA"
"PMID28325643","Anquetil et al. (2017)","Il1b","protein","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Reported as difference of the mean intensity in the positive area (MIP), and the mean intensity in the negative area (MIN, background)","MIP-MIN",,"0","0"," IL-1beta mRNA expression is independent of BMI and disease status","NA","no","IF",,"interval",,,,"NA"
"PMID28323930","Lam et al. (2017)","Ins.cells","cell","type B pancreatic cell",0,"Yes",1,"NA","NA","NA",,"MP:0009255","degranulated pancreatic beta cells","Count of total Insulin+ beta cells","count","beta cell persistence","1","1",,,,,,"interval",,,"Supplemental Table 10: Beta-cell death.","https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/102/8/10.1210_jc.2016-3806/1/jc.2016-3806_Supplemental_Table_1-14.xlsx?Expires=1521155148&Signature=Gl0xp87IMGbQE1zah6aRz-lHuJU6ffk0HGoiq-oF6VVKtfJMtBt9MkR9IKlsXA52~vD7IHsYpcLfBqQlABbYBTEF3suFfag97PErpOI4RGmtWWyEmBHAL2Js~KJ9hkRlQrp5ixDZwcR0olmiw6r1KSi8HEC0kevDRHLUwvaoX6dscyNQLeQiIEMp9WrQ4ZFbuI1COfilS5lrmjJUMIPNSJb5bAXRRP8DK1ZWpcuIY-D7AsBCjk56Tgthn51YggrJrMrLvv0smQndo7rmdiIIFoal8NddkpmAI~S31r5bktI2NYjXES71~gcyFol1fFVb-QkzI30UT6GOhWLCON~Hdw__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q"
"PMID28323930","Lam et al. (2017)","TUNEL.Ins.cells","cell","type B pancreatic cell",0,"Yes",0.5,"NA","NA","NA",,,,"Quantification of beta cell turnover by measurement of TUNEL+ Ins+ beta-cells and reported as % total cells","%","beta cell neogenesis","0","0",,"0-100","no",,,"interval",,,"Supplemental Table 10: Beta-cell death.","https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/102/8/10.1210_jc.2016-3806/1/jc.2016-3806_Supplemental_Table_1-14.xlsx?Expires=1521155148&Signature=Gl0xp87IMGbQE1zah6aRz-lHuJU6ffk0HGoiq-oF6VVKtfJMtBt9MkR9IKlsXA52~vD7IHsYpcLfBqQlABbYBTEF3suFfag97PErpOI4RGmtWWyEmBHAL2Js~KJ9hkRlQrp5ixDZwcR0olmiw6r1KSi8HEC0kevDRHLUwvaoX6dscyNQLeQiIEMp9WrQ4ZFbuI1COfilS5lrmjJUMIPNSJb5bAXRRP8DK1ZWpcuIY-D7AsBCjk56Tgthn51YggrJrMrLvv0smQndo7rmdiIIFoal8NddkpmAI~S31r5bktI2NYjXES71~gcyFol1fFVb-QkzI30UT6GOhWLCON~Hdw__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q"
"PMID28323930","Lam et al. (2017)","Ins.cells","cell","type B pancreatic cell",0,"Yes",1,"NA","NA","NA",,"MP:0020578","abnormal pancreatic beta cell number","Count of beta cells","count",,"1","1",,,,,,"interval",,,"Supplemental Table 4: Non-diabetic beta-cell area and mass. & Supplemental Table 5: T1D beta-cell area and mass.","https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/102/8/10.1210_jc.2016-3806/1/jc.2016-3806_Supplemental_Table_1-14.xlsx?Expires=1521155148&Signature=Gl0xp87IMGbQE1zah6aRz-lHuJU6ffk0HGoiq-oF6VVKtfJMtBt9MkR9IKlsXA52~vD7IHsYpcLfBqQlABbYBTEF3suFfag97PErpOI4RGmtWWyEmBHAL2Js~KJ9hkRlQrp5ixDZwcR0olmiw6r1KSi8HEC0kevDRHLUwvaoX6dscyNQLeQiIEMp9WrQ4ZFbuI1COfilS5lrmjJUMIPNSJb5bAXRRP8DK1ZWpcuIY-D7AsBCjk56Tgthn51YggrJrMrLvv0smQndo7rmdiIIFoal8NddkpmAI~S31r5bktI2NYjXES71~gcyFol1fFVb-QkzI30UT6GOhWLCON~Hdw__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q"
"PMID28323930","Lam et al. (2017)","Ki67.Ins.cells","cell","type B pancreatic cell",0,"Yes",1,"NA","NA","NA",,"MP:0011818","abnormal pancreatic beta cell proliferation","Quantification of beta cell turnover by Ki67+ staining and reported as % of total cells","%","beta cell neogenesis","0","0",,"0-100","no","IF",,"interval",,,"Supplemental Table 7: Individual ?-cell and acinar cell proliferation from non-diabetic pancreata. & Supplemental Table 8: Individual ?-cell and acinar cell proliferation from T1D pancreta.","https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/102/8/10.1210_jc.2016-3806/1/jc.2016-3806_Supplemental_Table_1-14.xlsx?Expires=1521155148&Signature=Gl0xp87IMGbQE1zah6aRz-lHuJU6ffk0HGoiq-oF6VVKtfJMtBt9MkR9IKlsXA52~vD7IHsYpcLfBqQlABbYBTEF3suFfag97PErpOI4RGmtWWyEmBHAL2Js~KJ9hkRlQrp5ixDZwcR0olmiw6r1KSi8HEC0kevDRHLUwvaoX6dscyNQLeQiIEMp9WrQ4ZFbuI1COfilS5lrmjJUMIPNSJb5bAXRRP8DK1ZWpcuIY-D7AsBCjk56Tgthn51YggrJrMrLvv0smQndo7rmdiIIFoal8NddkpmAI~S31r5bktI2NYjXES71~gcyFol1fFVb-QkzI30UT6GOhWLCON~Hdw__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q"
"PMID28323930","Lam et al. (2017)","Arx.cells","cell","pancreatic acinar cell",0,"Yes",1,"NA","NA","NA",,"MP:0009155","pancreatic acinar hyperplasia","Count of acinar cells","count",,"0","0",,,,,,,,,"Supplemental Table 7: Individual ?-cell and acinar cell proliferation from non-diabetic pancreata. & Supplemental Table 8: Individual ?-cell and acinar cell proliferation from T1D pancreta.","https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/102/8/10.1210_jc.2016-3806/1/jc.2016-3806_Supplemental_Table_1-14.xlsx?Expires=1521155148&Signature=Gl0xp87IMGbQE1zah6aRz-lHuJU6ffk0HGoiq-oF6VVKtfJMtBt9MkR9IKlsXA52~vD7IHsYpcLfBqQlABbYBTEF3suFfag97PErpOI4RGmtWWyEmBHAL2Js~KJ9hkRlQrp5ixDZwcR0olmiw6r1KSi8HEC0kevDRHLUwvaoX6dscyNQLeQiIEMp9WrQ4ZFbuI1COfilS5lrmjJUMIPNSJb5bAXRRP8DK1ZWpcuIY-D7AsBCjk56Tgthn51YggrJrMrLvv0smQndo7rmdiIIFoal8NddkpmAI~S31r5bktI2NYjXES71~gcyFol1fFVb-QkzI30UT6GOhWLCON~Hdw__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q"
"PMID28323930","Lam et al. (2017)","Ki67.Arx.cells","cell","pancreatic acinar cell",0,"Yes",1,"NA","NA","NA",,"MP:0009155","pancreatic acinar hyperplasia","Quantification of acinar cell proliferation by Ki67+ staining and reported as % of total cells","%","beta cell neogenesis","0","0",,"0-100","no","IF",,"interval",,,"Supplemental Table 7: Individual ?-cell and acinar cell proliferation from non-diabetic pancreata. & Supplemental Table 8: Individual ?-cell and acinar cell proliferation from T1D pancreta.","https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/102/8/10.1210_jc.2016-3806/1/jc.2016-3806_Supplemental_Table_1-14.xlsx?Expires=1521155148&Signature=Gl0xp87IMGbQE1zah6aRz-lHuJU6ffk0HGoiq-oF6VVKtfJMtBt9MkR9IKlsXA52~vD7IHsYpcLfBqQlABbYBTEF3suFfag97PErpOI4RGmtWWyEmBHAL2Js~KJ9hkRlQrp5ixDZwcR0olmiw6r1KSi8HEC0kevDRHLUwvaoX6dscyNQLeQiIEMp9WrQ4ZFbuI1COfilS5lrmjJUMIPNSJb5bAXRRP8DK1ZWpcuIY-D7AsBCjk56Tgthn51YggrJrMrLvv0smQndo7rmdiIIFoal8NddkpmAI~S31r5bktI2NYjXES71~gcyFol1fFVb-QkzI30UT6GOhWLCON~Hdw__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q"
"PMID28323930","Lam et al. (2017)","Nkx61.Arx.cells","cell","pancreatic ductal cell",0,"Yes",0.5,"NA","NA","NA",,,,"Quantification of islet ductal neogenesis by staining for Nkx6.1+/Arx+ cells and reported as % total cells","%","beta cell neogenesis","0","0",,"0-100","no","IF","Islet images were classified into three possible categories: (1) solitary insulin-positive ? cell in duct; (2) insulin-positive islet in duct; and (3) insulin-positive islets not associated with ducts. Results were quantified per individual and expressed as percent total islets.","interval",,,"Supplemental Table 12: No evidence of ?-cell Neogenesis in T1D Pancreata.","https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/102/8/10.1210_jc.2016-3806/1/jc.2016-3806_Supplemental_Table_1-14.xlsx?Expires=1521155148&Signature=Gl0xp87IMGbQE1zah6aRz-lHuJU6ffk0HGoiq-oF6VVKtfJMtBt9MkR9IKlsXA52~vD7IHsYpcLfBqQlABbYBTEF3suFfag97PErpOI4RGmtWWyEmBHAL2Js~KJ9hkRlQrp5ixDZwcR0olmiw6r1KSi8HEC0kevDRHLUwvaoX6dscyNQLeQiIEMp9WrQ4ZFbuI1COfilS5lrmjJUMIPNSJb5bAXRRP8DK1ZWpcuIY-D7AsBCjk56Tgthn51YggrJrMrLvv0smQndo7rmdiIIFoal8NddkpmAI~S31r5bktI2NYjXES71~gcyFol1fFVb-QkzI30UT6GOhWLCON~Hdw__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q"
"PMID28323930","Lam et al. (2017)","Ins.Gcg.cells","cell","type B pancreatic cell|pancreatic A cell",0,"Yes",0.5,"NA","NA","NA",,,,"Number of insulin-glucagon coexpressing cells ","count","beta cell dedifferentiation","0","0",,"NA","no",,,"interval",,,"Supplemental Table 13: Insulin-glucagon coexpressing cells from non-diabetic and T1D samples.","https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/102/8/10.1210_jc.2016-3806/1/jc.2016-3806_Supplemental_Table_1-14.xlsx?Expires=1521155148&Signature=Gl0xp87IMGbQE1zah6aRz-lHuJU6ffk0HGoiq-oF6VVKtfJMtBt9MkR9IKlsXA52~vD7IHsYpcLfBqQlABbYBTEF3suFfag97PErpOI4RGmtWWyEmBHAL2Js~KJ9hkRlQrp5ixDZwcR0olmiw6r1KSi8HEC0kevDRHLUwvaoX6dscyNQLeQiIEMp9WrQ4ZFbuI1COfilS5lrmjJUMIPNSJb5bAXRRP8DK1ZWpcuIY-D7AsBCjk56Tgthn51YggrJrMrLvv0smQndo7rmdiIIFoal8NddkpmAI~S31r5bktI2NYjXES71~gcyFol1fFVb-QkzI30UT6GOhWLCON~Hdw__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q"
"PMID28323930","Lam et al. (2017)","beta.area","cell","type B pancreatic cell",0,"Yes",1,"NA","NA","NA",,"MP:0020578","abnormal pancreatic beta cell number","Beta cell area reported as % total pancreas sections analyzed","%",,"1","1",,"NA","no",,,"interval",,,"Supplemental Table 4: Non-diabetic beta-cell area and mass. & Supplemental Table 5: T1D beta-cell area and mass.","https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/102/8/10.1210_jc.2016-3806/1/jc.2016-3806_Supplemental_Table_1-14.xlsx?Expires=1521155148&Signature=Gl0xp87IMGbQE1zah6aRz-lHuJU6ffk0HGoiq-oF6VVKtfJMtBt9MkR9IKlsXA52~vD7IHsYpcLfBqQlABbYBTEF3suFfag97PErpOI4RGmtWWyEmBHAL2Js~KJ9hkRlQrp5ixDZwcR0olmiw6r1KSi8HEC0kevDRHLUwvaoX6dscyNQLeQiIEMp9WrQ4ZFbuI1COfilS5lrmjJUMIPNSJb5bAXRRP8DK1ZWpcuIY-D7AsBCjk56Tgthn51YggrJrMrLvv0smQndo7rmdiIIFoal8NddkpmAI~S31r5bktI2NYjXES71~gcyFol1fFVb-QkzI30UT6GOhWLCON~Hdw__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q"
"PMID28323930","Lam et al. (2017)","beta.mass","cell","type B pancreatic cell",0,"Yes",1,"NA","NA","NA",,"MP:0009112","abnormal pancreatic beta cell mass","Beta cell mass in grams","g",,"1","1",,"0-100","no",,"Calculated from area stained and adjusted by known pancreas weight.","interval",,,"Supplemental Table 4: Non-diabetic beta-cell area and mass. & Supplemental Table 5: T1D beta-cell area and mass.","https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/102/8/10.1210_jc.2016-3806/1/jc.2016-3806_Supplemental_Table_1-14.xlsx?Expires=1521155148&Signature=Gl0xp87IMGbQE1zah6aRz-lHuJU6ffk0HGoiq-oF6VVKtfJMtBt9MkR9IKlsXA52~vD7IHsYpcLfBqQlABbYBTEF3suFfag97PErpOI4RGmtWWyEmBHAL2Js~KJ9hkRlQrp5ixDZwcR0olmiw6r1KSi8HEC0kevDRHLUwvaoX6dscyNQLeQiIEMp9WrQ4ZFbuI1COfilS5lrmjJUMIPNSJb5bAXRRP8DK1ZWpcuIY-D7AsBCjk56Tgthn51YggrJrMrLvv0smQndo7rmdiIIFoal8NddkpmAI~S31r5bktI2NYjXES71~gcyFol1fFVb-QkzI30UT6GOhWLCON~Hdw__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q"
"PMID28213757","Willcox et al. (2017)","germinal.c.freq","cell","lymph node follicle",0,"Contact authors",0,"NA","NA","NA",,,,"Percent follicles with germinal center","%",,"1","1",,"0-100","no","IF",,"interval",,,"Fig. 3","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487689/figure/Fig3/"
"PMID28154952","Martin et al. (2017)","Nitrotyrosine","protein","islet of Langerhans",0,"Yes",1,"NA","NA","NA",,,,"Nitrotyrosine expression as percentage of insulin-positive islets with nitrotyrosine staining","%",,"1","1","Nitrotyrosine immunostaining is independent of the presence and severity of insulitis","0-100","no","IF",,"interval",,,"Fig 4: Non-diabetic autoantibody-negative nPOD cases showing the percentage of insulin-positive islets with nitrotyrosine. & Fig 6: Non-diabetic autoantibody-positive nPOD cases showing the percentage of insulin-positive islets with nitrotyrosine.","https://link.springer.com/article/10.1007%2Fs00418-016-1533-5#Fig4|https://link.springer.com/article/10.1007%2Fs00418-016-1533-5#Fig6"
"PMID28137793","Rodriguez-Calvo et al. (2017)","Ins","protein","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Measured by staining and reported as % positive area","%",,"NA","NA",,"0-100","no","immunostaining",,"interval",,,,"http://diabetes.diabetesjournals.org/content/diabetes/66/5/1334/F1.large.jpg?width=800&height=600&carousel=1"
"PMID28137793","Rodriguez-Calvo et al. (2017)","Proins","protein","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Measured by staining and reported as % positive area","%",,"NA","1",,"0-100","no","immunostaining",,"interval",,,,"http://diabetes.diabetesjournals.org/content/diabetes/66/5/1334/F1.large.jpg?width=800&height=600&carousel=1"
"PMID28137793","Rodriguez-Calvo et al. (2017)","Gcg","protein","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Measured by staining and reported as % positive area","%",,"NA","NA",,"0-100","no","immunostaining",,"interval",,,,"http://diabetes.diabetesjournals.org/content/diabetes/66/5/1334/F1.large.jpg?width=800&height=600&carousel=1"
"PMID28094469","Kirk et al. (2017)","GLP1R.prct.acinar","protein","pancreatic ductal cell",0,"Yes",1,"NA","NA","NA",,,,"GLP-1R+ cells in or near ducts (% of total duct cells)","%",,"1","1",,"0-100","no","immunostaining",,"interval",,,"Table 2: GLP-1R expression levels.","https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.12879"
"PMID28094469","Kirk et al. (2017)","GLP1R.prct.islets","protein","pancreatic ductal cell",0,"Yes",1,"NA","NA","NA",,,,"GLP-1R+ cells in islets (% of total pancreas area)","%",,"1","1","Glucagon-like peptide-1 (GLP-1) has beta-cell protective effects and can be assessed by a new monoclonal antibody in pancreatic tissue","0-100","no","immunostaining","A software-based automated image analysis algorithm was used for quantitating intensities and area fractions of GLP-1R positive compartments.","interval",,,"Table 2: GLP-1R expression levels.","https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.12879"
"PMID28094469","Kirk et al. (2017)","GLP1R.acinar","protein","pancreatic acinar cell",0,"Yes",1,"NA","NA","NA",,,,"Average intensity of GLP-1R+ acinar cells",,,"1","1",,"NA","no","immunostaining",,"interval",,,"Table 2: GLP-1R expression levels.","https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.12879"
"PMID28094469","Kirk et al. (2017)","GLP1R.islet","protein","islet of Langerhans",0,"Yes",1,"NA","NA","NA",,,,"Average intensity of GLP-1R+ cells in islets",,,"1","1",,"NA","no","immunostaining",,"interval",,,"Table 2: GLP-1R expression levels.","https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.12879"
"PMID27942583","Seay et al. (2016)","Immunosequencing","peptide",,1,"Yes",0.5,"NA","NA","NA",,,,,,,"1","1",,"NA","no","immunosequencing",,,,,"nPOD TCR/BCR Search","http://clonesearch.jdrfnpod.org/"
"PMID27942583","Seay et al. (2016)","Bcell.PBMC.PC","phenotype",,0,,1,,,,,,,,,,,,,,,,,,,,,
"PMID27942583","Seay et al. (2016)","Bcell.Spleen.PC","phenotype",,0,,1,,,,,,,,,,,,,,,,,,,,,
"PMID27942583","Seay et al. (2016)","Bcell.iLN.PC","phenotype",,0,,1,,,,,,,,,,,,,,,,,,,,,
"PMID27942583","Seay et al. (2016)","Bcell.pLN.PC","phenotype",,0,,1,,,,,,,,,,,,,,,,,,,,,
"PMID27942583","Seay et al. (2016)","CD4Tcell.Intraislet.PC","phenotype",,0,,1,,,,,,,,,,,,,,,,,,,,,
"PMID27942583","Seay et al. (2016)","CD8Tcell.Intraislet.PC","phenotype",,0,,1,,,,,,,,,,,,,,,,,,,,,
"PMID27942583","Seay et al. (2016)","CD8Tcell.PBMC.PC","phenotype",,0,,1,,,,,,,,,,,,,,,,,,,,,
"PMID27942583","Seay et al. (2016)","CD8Tcell.Spleen.PC","phenotype",,0,,1,,,,,,,,,,,,,,,,,,,,,
"PMID27942583","Seay et al. (2016)","CD8Tcell.iLN.PC","phenotype",,0,,1,,,,,,,,,,,,,,,,,,,,,
"PMID27942583","Seay et al. (2016)","CD8Tcell.pLN.PC","phenotype",,0,,1,,,,,,,,,,,,,,,,,,,,,
"PMID27942583","Seay et al. (2016)","Tconv.PBMC.PC","phenotype",,0,,1,,,,,,,,,,,,,,,,,,,,,
"PMID27942583","Seay et al. (2016)","Tconv.Spleen.PC","phenotype",,0,,1,,,,,,,,,,,,,,,,,,,,,
"PMID27942583","Seay et al. (2016)","Tconv.iLN.PC","phenotype",,0,,1,,,,,,,,,,,,,,,,,,,,,
"PMID27942583","Seay et al. (2016)","Tconv.pLN.PC","phenotype",,0,,1,,,,,,,,,,,,,,,,,,,,,
"PMID27942583","Seay et al. (2016)","Treg.PBMC.PC","phenotype",,0,,1,,,,,,,,,,,,,,,,,,,,,
"PMID27942583","Seay et al. (2016)","Treg.Spleen.PC","phenotype",,0,,1,,,,,,,,,,,,,,,,,,,,,
"PMID27942583","Seay et al. (2016)","Treg.iLN.PC","phenotype",,0,,1,,,,,,,,,,,,,,,,,,,,,
"PMID27942583","Seay et al. (2016)","Treg.pLN.PC","phenotype",,0,,1,,,,,,,,,,,,,,,,,,,,,
"PMID27813705","Moin et al. (2016)","Ki67.PDG","cell","pancreatic ductal cell",0,"Yes",1,"NA","NA","NA",,"MP:0009143","abnormal pancreatic duct morphology","PDG Cell proliferation (% Ki67+ PDG cells)","%","beta cell neogenesis","1","1",,"0-100",,"immunostaining",,"interval",,,"Table 1: Characteristics of Human Subjects With and Without T1D","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413103/table/T1/"
"PMID27813705","Moin et al. (2016)","Ki67.interPDG","cell","pancreatic ductal cell",0,"Yes",0,"NA","NA","NA",,,,"Interlobular duct cell proliferation (% Ki67+ interlobular duct cells)","%","beta cell neogenesis","NA","1",,"0-100","no","immunostaining",,"interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413103/figure/F2/"
"PMID27813705","Moin et al. (2016)","Ki67.intraPDG","cell","pancreatic ductal cell",0,"Yes",0,"NA","NA","NA",,,,"Intralobular duct cell proliferation (% Ki67+ intralobular duct cells)","%","beta cell neogenesis","NA","1",,"0-100","no","immunostaining",,"interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413103/figure/F2/"
"PMID27813705","Moin et al. (2016)","Ins.interPDG","cell","pancreatic ductal cell",0,"Yes",0,"NA","NA","NA",,,,"Beta cell neogenesis from interlobular duct cells (% Ins+ interlobular duct cells)","%","beta cell neogenesis","NA","1",,"0-100","no","immunostaining",,"interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413103/figure/F2/"
"PMID27813705","Moin et al. (2016)","Ins.intraPDG","cell","pancreatic ductal cell",0,"Yes",0,"NA","NA","NA",,,,"Beta cell neogenesis from intralobular duct cells (% Ins+ intralobular duct cells)","%","beta cell neogenesis","NA","1",,"0-100","no","immunostaining",,"interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413103/figure/F2/"
"PMID27813705","Moin et al. (2016)","Sox9.PDG","cell","pancreatic duct",0,"Contact authors",0,"NA","NA","NA",,,,"Presence of pancreatic progenitors in pancreatic duct glands (% Sox9+ PDG cells)","%","beta cell neogenesis","0","0",,"0-100","no","immunostaining",,"interval",,,,"NA"
"PMID27813705","Moin et al. (2016)","Gata4.PDG","cell","pancreatic duct",0,"Contact authors",0,"NA","NA","NA",,,,"Presence of pancreatic progenitors in pancreatic duct glands (%GATA4+ PDG cells)","%","beta cell neogenesis","0","0",,"0-100","no","immunostaining",,"interval",,,,"NA"
"PMID27809303","Piran et al. (2016)","Par2","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"PAR2 expression",,,"0","1",,"NA","no","immunostaining",,"NA",,,,"NA"
"PMID27798614","Babon et al. (2016)","Autoreactivity","phenotype",,1,"Contact authors",0,"NA","NA","NA",,,,"Autoreactivity of CD4+ and CD8+ T cell lines and clones sorted or directly grown from islets from donors, measured as production of IFNgamma","pg/mL",,"1","1",,"NA","no","chemokine assay",,"interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5140746/figure/F2/"
"PMID27506584","Richardson et al. (2016)","HLA.A1","transcript",,0,"Yes",1,"3105","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.A1",,"HLA","1","1","No statistically significant differences between T1D vs Controls","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.A2","transcript",,0,"Yes",1,"3105","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.A2",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.A3","transcript",,0,"Yes",1,"3105","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.A3",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.A4","transcript",,0,"Yes",1,"3105","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.A4",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.A5","transcript",,0,"Yes",1,"3105","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.A5",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.A6","transcript",,0,"Yes",1,"3105","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.A6",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.A7","transcript",,0,"Yes",1,"3105","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.A7",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.A8","transcript",,0,"Yes",1,"3105","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.A7",,"HLA","1","1","No statistically significant differences between T1D vs Controls","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.B1","transcript",,0,"Yes",1,"3106","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.B1",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.B2","transcript",,0,"Yes",1,"3106","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.B2",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.B3","transcript",,0,"Yes",1,"3106","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.B3",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.B4","transcript",,0,"Yes",1,"3106","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.B4",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.B5","transcript",,0,"Yes",1,"3106","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.B5",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.B6","transcript",,0,"Yes",1,"3106","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.B6",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.C1","transcript",,0,"Yes",1,"3107","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.C1",,"HLA","1","1","No statistically significant differences between T1D vs Controls","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.C2","transcript",,0,"Yes",1,"3107","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.C2",,"HLA","1","1","No statistically significant differences between T1D vs Controls","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.C3","transcript",,0,"Yes",1,"3107","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.C3",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.C4","transcript",,0,"Yes",1,"3107","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.C4",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.C5","transcript",,0,"Yes",1,"3107","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.C5",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.C6","transcript",,0,"Yes",1,"3107","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.C6",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.C7","transcript",,0,"Yes",1,"3107","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.C7",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.F1","transcript",,0,"Yes",1,"3134","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.F1",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.F2","transcript",,0,"Yes",1,"3134","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.F2",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.F3","transcript",,0,"Yes",1,"3134","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.F3",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.F4","transcript",,0,"Yes",1,"3134","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.F4",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.F5","transcript",,0,"Yes",1,"3134","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.F5",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.F6","transcript",,0,"Yes",1,"3134","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.F6",,"HLA","1","1","Hyperexpression observed in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","HLA.F7","transcript",,0,"Yes",1,"3134","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of HLA.F7",,"HLA","1","1","No statistically significant differences between T1D vs Controls","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","B2M","transcript",,0,"Yes",1,"567","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Relative RNA expression of B2M",,,"0","1","Expression of beta2-microglobulin (a second component required for the generation of functional HLA class I complexes) elevated in T1D","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","NLRC5","transcript",,0,"Yes",1,"84166","NA","NA",,,,"Relative RNA expression of NLRC5",,,"0","0","No statistically significant differences between T1D vs controls","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","STAT1","transcript",,0,"Yes",1,"6772","NA","NA",,,,"Relative RNA expression of STAT1",,,"1","1","Higher in T1D than controls; positive correlation between STAT1 and HLA-ABC expression; decreases with disease duration","NA","no",,,"interval",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","IHC.score","phenotype",,0,"Yes",1,"NA","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Overall score of overall HLA expression in islets","score",,"1","1","Higher in T1D than controls","0-2","0=normal expression; 1=elevated expression; 2=hyperexpression",,,"ordinal",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27506584","Richardson et al. (2016)","ICI.score","phenotype",,0,"Yes",1,"NA","NA","NA",,"MP:0020578","abnormal pancreatic beta cell number","Overall score of insulin immunopositivity in islets","score",,"1","1","Variable but generally lower insulin immunopositivity in T1D vs controls","0-3","The ICI score relates to the number of residual ICIs in the nearest available block for assessment (+++ >20 ICIs; ++ 10-20 ICIs; + 1-10 ICIs, -No ICIs).",,,"ordinal",,,"ESM Figure 5: Heat map of relative RNA expression of the HLA-A, B, C , F, beta2M, STAT1 genes examined in nPODcontrols and nPOD Type 1 diabetes patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042874/bin/125_2016_4067_MOESM1_ESM.pdf"
"PMID27300574","Moin et al. (2016)","CgA.cells","cell",,0,"Contact authors",0,"NA","NA","NA",,,,"Frequency of chromogranin-positive, hormone-negative (CPHN) cells in islets","% CPHN cells in islets",,"1","1",,"0-100","no","immunostaining",,"ordinal",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010569/figure/F2/"
"PMID27300574","Moin et al. (2016)","CgA.cluster","cell",,0,"Contact authors",0,"NA","NA","NA",,,,"Frequency of chromogranin-positive, hormone-negative (CPHN) cells in scattered clusters of endocrine cells","% CPHN in clusters",,"1","1",,"0-100","no","immunostaining",,"ordinal",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010569/figure/F2/"
"PMID27300574","Moin et al. (2016)","CgA.section","cell",,0,"Contact authors",0,"NA","NA","NA",,,,"Frequency of chromogranin-positive, hormone-negative (CPHN) cells in scattered clusters of endocrine cells","count of CPHN cells/mm^2 of pancreas section",,"1","1",,"NA","no","immunostaining",,"ordinal",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010569/figure/F2/"
"PMID27284108","Phelps et al. (2016)","GAD65.ratio","protein",,0,"Yes",1,"2572","NA","NA",,,,"GAD65 localization as Golgi:Cell mean fluorescence intensity (MFI) ratio","ratio",,"1","1","Distribution of GAD65 changes under ER stress – appears to accumulate in Golgi","NA","no","immunostaining","The ratio of GAD65 mean fluorescence intensity (MFI) in the Golgi compartment and post-Golgi vesicles compared with the rest of the cytosol was calculated with a custom ImageJ macro. Individual B-cells in a given field of view were identified and outlined by hand. For each cell, the macro automatically defined a region of interest (ROI) outlining the Golgi compartment, identified by giantin costain or by characteristic morphology and brightness thresholding of GAD65 stain, and GAD65+ vesicles, identified by brightness thresholding of GAD65+ bright puncta. A second ROI defined the remainder of the cell, excluding the Golgi, GAD65+ vesicles, and nucleus. GAD65 Golgi accumulation was reported as the ratio of MFI for the two ROIs.","interval",,,"Supplementary Table 1 & Supplementary Table 2 & Supplementary Table 3","http://diabetes.diabetesjournals.org/highwire/filestream/75457/field_highwire_adjunct_files/0/DB160180SupplementaryData.pdf"
"PMID26950362","Helman et al. (2016)","p16","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"staining intensity",,,,,,"NA","no","immunostaining",,"interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546206/bin/NIHMS872711-supplement-Supplemental_Tables.pdf"
"PMID26950362","Helman et al. (2016)","Cox17","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"staining intensity",,,,,,"NA","no","immunostaining",,"interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546206/bin/NIHMS872711-supplement-Supplemental_Tables.pdf"
"PMID26950362","Helman et al. (2016)","pS6","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"staining intensity",,,,,,"NA","no","immunostaining",,"interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546206/bin/NIHMS872711-supplement-Supplemental_Tables.pdf"
"PMID26950362","Helman et al. (2016)","Ndufb5","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"staining intensity",,,,,,"NA","no","immunostaining",,"interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546206/bin/NIHMS872711-supplement-Supplemental_Tables.pdf"
"PMID26950362","Helman et al. (2016)","Atp5a","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"staining intensity",,,,,,"NA","no","immunostaining",,"interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546206/bin/NIHMS872711-supplement-Supplemental_Tables.pdf"
"PMID26935967","Liu et al. (2016)","Proteomics","protein","exocrine pancreas",1,"Yes",1,"NA","NA","NA",,,,"Proteomics of pancreatic head region tissues, expression values for 5357 proteins","NA",,"NA","1","Among the 5357 (1% false discovery rate) confidently identified proteins, 145 showed statistically significant dysregulation between T1D and healthy subjects","NA","no","TMT10;LC-MS","Approximately 30 mg of tissue from each sample were processed for TMT10-based isobaric labeling and multidimensional LC-MS/MS was used for peptide analysis.","interval",,,"Table S1: 5368 protein groups identified in pancreatic tissue.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893790/bin/NIHMS788696-supplement-supplemental_information.pdf"
"PMID26858360","Leete et al. (2016)","CD20.cat","cell",,0,"Yes",1,"NA","NA","NA",,"MP:0004031","insulitis","Ratio of CD20+:CD4+ cells in inflamed islets, reported as 0 = CD20Lo or 1 = CD20Hi","[Lo,Hi]",,"1","1",,"0-1","yes","immunostaining",,"ordinal",,,,"http://diabetes.diabetesjournals.org/content/65/5/1362.long"
"PMID26581594","Campbell-Thompson et al. (2015)","InsNeg.CD3Pos","cell","islet of Langerhans",0,,1,"NA","NA","NA",,"MP:0004031","insulitis","Number of islets counted that are insulin-negative and CD3-positive",,,,,,,,,"Multiple slide sections were reviewed from each donor pancreas, and islets were counted by insulin immunopositivity (Ins+, Ins−) and insulitis status (CD3−, CD3+). Screening for insulitic islets was performed on CD3+ glucagon–stained sections. An islet was defined as ≥10 α-cells. Insulitis was defined as an islet with six or more CD3+ cells immediately adjacent to or within the islet with three or more islets per pancreas section.","interval",,,"Table 1: Insulitis frequency in donors","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764143/table/T1/"
"PMID26581594","Campbell-Thompson et al. (2015)","InsPos.CD3Pos","cell","islet of Langerhans",0,,1,"NA","NA","NA",,"MP:0004031","insulitis","Number of islets counted that are insulin-positive and CD3-positive",,,,,,,,,"Multiple slide sections were reviewed from each donor pancreas, and islets were counted by insulin immunopositivity (Ins+, Ins−) and insulitis status (CD3−, CD3+). Screening for insulitic islets was performed on CD3+ glucagon–stained sections. An islet was defined as ≥10 α-cells. Insulitis was defined as an islet with six or more CD3+ cells immediately adjacent to or within the islet with three or more islets per pancreas section.","interval",,,"Table 1: Insulitis frequency in donors","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764143/table/T1/"
"PMID26581594","Campbell-Thompson et al. (2015)","InsNeg.CD3Neg","cell","islet of Langerhans",0,,1,"NA","NA","NA",,"MP:0004031","insulitis","Number of islets counted that are insulin-negative and CD3-negative",,,,,,,,,"Multiple slide sections were reviewed from each donor pancreas, and islets were counted by insulin immunopositivity (Ins+, Ins−) and insulitis status (CD3−, CD3+). Screening for insulitic islets was performed on CD3+ glucagon–stained sections. An islet was defined as ≥10 α-cells. Insulitis was defined as an islet with six or more CD3+ cells immediately adjacent to or within the islet with three or more islets per pancreas section.","interval",,,"Table 1: Insulitis frequency in donors","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764143/table/T1/"
"PMID26581594","Campbell-Thompson et al. (2015)","InsPos.CD3Neg","cell","islet of Langerhans",0,,1,"NA","NA","NA",,"MP:0004031","insulitis","Number of islets counted that are insulin-positive and CD3-negative",,,,,,,,,"Multiple slide sections were reviewed from each donor pancreas, and islets were counted by insulin immunopositivity (Ins+, Ins−) and insulitis status (CD3−, CD3+)","interval",,,"Table 1: Insulitis frequency in donors","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764143/table/T1/"
"PMID26581594","Campbell-Thompson et al. (2015)",0,"cell","islet of Langerhans",0,"Yes",1,"NA","NA","NA",,"MP:0004031","insulitis","Percent of islets with insulitis (with six or more CD3+ cells)","%",,,,,,,"immunostaining","Calculated as sum insulitic islets: (Ins+ CD3+ and Ins− CD3+)/total islets","interval",,,"Table 1: Insulitis frequency in donors","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764143/table/T1/"
"PMID26581594","Campbell-Thompson et al. (2015)","InsPos.CD3.prct","cell","islet of Langerhans",0,"Yes",1,"NA","NA","NA",,"MP:0004031","insulitis","Percent of insulin-positive islets with insulitis (with six or more CD3+ cells)","%",,,,,,,,,"interval",,"This is a derived-feature calculated for purposes of comparison with Reddy et al. (2015).","Table 1: Insulitis frequency in donors","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764143/table/T1/"
"PMID26581594","Campbell-Thompson et al. (2015)","beta.mass","cell","type B pancreatic cell",0,"Contact authors",0,"NA","NA","NA",,,,"Beta cell mass","mg",,,,"B-cell mass was decreased in donors with T1D, regardless of insulitis status, compared with those without T1D; however, B-cell mass was significantly higher in T1D donors with insulitis compared with those without insulitis",,,,,"interval",,,"Figure 6","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764143/figure/F6/"
"PMID26581594","Campbell-Thompson et al. (2015)","alpha.mass","cell","pancreatic A cell",0,"Contact authors",0,"NA","NA","NA",,,,"Alpha cell mass","mg",,,,,,,,"Numbers of CD45+, CD3+, CD20+, CD8+, and CD4+ cells were counted for each insulitic islet and averaged per donor (2–10 islets/donor).",,,,"Figure 6","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764143/figure/F6/"
"PMID26581594","Campbell-Thompson et al. (2015)","CD45.cells.islet","cell","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,"MP:0004031","insulitis","CD45+ cells per islet",,,,,,,,,"Numbers of CD45+, CD3+, CD20+, CD8+, and CD4+ cells were counted for each insulitic islet and averaged per donor (2–10 islets/donor).",,,,"Figure 5","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764143/figure/F5/"
"PMID26581594","Campbell-Thompson et al. (2015)","CD3.cells.islet","cell","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,"MP:0004031","insulitis","CD3+ cells per islet",,,,,,,,,"Numbers of CD45+, CD3+, CD20+, CD8+, and CD4+ cells were counted for each insulitic islet and averaged per donor (2–10 islets/donor).",,,,"Figure 5","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764143/figure/F5/"
"PMID26581594","Campbell-Thompson et al. (2015)","CD20.cells.islet","cell","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,"MP:0004031","insulitis","CD20+ cells per islet",,,,,,,,,"Numbers of CD45+, CD3+, CD20+, CD8+, and CD4+ cells were counted for each insulitic islet and averaged per donor (2–10 islets/donor).",,,,"Figure 5","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764143/figure/F5/"
"PMID26581594","Campbell-Thompson et al. (2015)","CD8.cells.islet","cell","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,"MP:0004031","insulitis","CD8+ cells per islet",,,,,,,,,"Numbers of CD45+, CD3+, CD20+, CD8+, and CD4+ cells were counted for each insulitic islet and averaged per donor (2–10 islets/donor).",,,,"Figure 5","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764143/figure/F5/"
"PMID26581594","Campbell-Thompson et al. (2015)","CD4.cells.islet","cell","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,"MP:0004031","insulitis","CD4+ cells per islet",,,,,,,,,"Numbers of CD45+, CD3+, CD20+, CD8+, and CD4+ cells were counted for each insulitic islet and averaged per donor (2–10 islets/donor).",,,,"Figure 5","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764143/figure/F5/"
"PMID26076035","van der Meulen et al. (2015)","Ucn3.cat","protein","type B pancreatic cell",0,"Yes",1,"114131","NA","NA",,,,"Expression of Urocortin3 (UCN3) in beta cells, staining intensity category","[Low,Intermediate,High]",,,,"Ucn3 is stored and co-released with insulin and potentiates glucose-stimulated somatostatin secretion via cognate receptors on delta cells; islets lacking endogenous Ucn3 have fewer delta cells, reduced somatostatin content, impaired somatostatin secretion, and exaggerated insulin release","NA","yes",,,"ordinal",,"This is a derived feature. Individual-level signal intensity images were extracted from supplemental files and clustered into Low, Intermediate, and High categories.","Supplemental Figure 7","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496282/bin/NIHMS686747-supplement-1.pdf"
"PMID26055066","Taniguchi et al. (2015)","CCD1.cat","protein",,0,"Yes",1,"595","NA","NA",,,,"Cyclin D1 expression as % of islet cells stained","%",,"1","1",,"0-100","Coded as 0 to 3: +, 1 to 30%; ++, 31 to 60%; +++, greather than 60%","immunostaining",,"interval",,,"Table 1: The extent of expression of cyclin-D1 and -D3 in islets from heart-beating or post mortem control donors. & Table 2: The extent of expression of cyclin-D1 and -D3 in islets from heart-beating or post mortem autoantibody-positive donors and those with type 1 diabetes.","https://link.springer.com/article/10.1007%2Fs00125-015-3645-1#Tab1|https://link.springer.com/article/10.1007%2Fs00125-015-3645-1#Tab2"
"PMID26055066","Taniguchi et al. (2015)","CCD3.cat","protein",,0,"Yes",1,"896","NA","NA",,,,"Cyclin D3 expression as % of islet cells stained","%",,"1","1",,"0-100","Coded as 0 to 3: +, 1 to 30%; ++, 31 to 60%; +++, greather than 60%","immunostaining",,"interval",,,"Table 1: The extent of expression of cyclin-D1 and -D3 in islets from heart-beating or post mortem control donors. & Table 2: The extent of expression of cyclin-D1 and -D3 in islets from heart-beating or post mortem autoantibody-positive donors and those with type 1 diabetes.","https://link.springer.com/article/10.1007%2Fs00125-015-3645-1#Tab1|https://link.springer.com/article/10.1007%2Fs00125-015-3645-1#Tab2"
"PMID25687234","Reddy et al. (2015)","CD45.cells","cell",,0,"Yes",1,"NA","NA","NA",,"MP:0004031","insulitis","Mean number of peri- and intra-islet leucocytes (CD45+) per islet","count",,"1","1",,"NA",,"immunostaining",,,,,"Table 3: Mean number of peri- and intra-islet leucocytes and the sum of the two in relation to insulin-positive and -negative islets and the percentage of islets with insulitis in insulin-positive and -negative islets in non-diabetic and diabetic cases.","https://link.springer.com/article/10.1007%2Fs00125-015-3519-6#Tab3"
"PMID25687234","Reddy et al. (2015)","CD45.cells.periislet","cell",,0,"Yes",1,"NA","NA","NA",,"MP:0004031","insulitis","Mean number of peri-islet leucocytes (CD45+) per islet","count",,"1","1",,"NA",,"immunostaining",,,,,"Table 3: Mean number of peri- and intra-islet leucocytes and the sum of the two in relation to insulin-positive and -negative islets and the percentage of islets with insulitis in insulin-positive and -negative islets in non-diabetic and diabetic cases.","https://link.springer.com/article/10.1007%2Fs00125-015-3519-6#Tab3"
"PMID25687234","Reddy et al. (2015)","CD45.cells.intraislet","cell",,0,"Yes",1,"NA","NA","NA",,"MP:0004031","insulitis","Mean number of intra-islet leucocytes (CD45+) per islet","count",,"1","1",,"NA",,"immunostaining",,,,,"Table 3: Mean number of peri- and intra-islet leucocytes and the sum of the two in relation to insulin-positive and -negative islets and the percentage of islets with insulitis in insulin-positive and -negative islets in non-diabetic and diabetic cases.","https://link.springer.com/article/10.1007%2Fs00125-015-3519-6#Tab3"
"PMID25687234","Reddy et al. (2015)","InsPos.CD45.cells","cell",,0,"Yes",1,"NA","NA","NA",,"MP:0004031","insulitis","Mean number of peri- and intra-islet leucocytes (CD45+) per insulin-positive islet","count",,"1","1",,"NA",,"immunostaining",,,,,"Table 3: Mean number of peri- and intra-islet leucocytes and the sum of the two in relation to insulin-positive and -negative islets and the percentage of islets with insulitis in insulin-positive and -negative islets in non-diabetic and diabetic cases.","https://link.springer.com/article/10.1007%2Fs00125-015-3519-6#Tab3"
"PMID25687234","Reddy et al. (2015)","InsNeg.CD45.cells","cell",,0,,1,"NA","NA","NA",,"MP:0004031","insulitis","Mean number of peri- and intra-islet leucocytes (CD45+) per insulin-negative islet",,,,,,,,,,,,,"Table 3: Mean number of peri- and intra-islet leucocytes and the sum of the two in relation to insulin-positive and -negative islets and the percentage of islets with insulitis in insulin-positive and -negative islets in non-diabetic and diabetic cases.","https://link.springer.com/article/10.1007%2Fs00125-015-3519-6#Tab3"
"PMID25687234","Reddy et al. (2015)","InsPos.CD45.cells.periislet","cell",,0,,1,"NA","NA","NA",,"MP:0004031","insulitis","Mean number of peri-islet leucocytes (CD45+) per insulin-positive islet",,,,,,,,,,,,,"Table 3: Mean number of peri- and intra-islet leucocytes and the sum of the two in relation to insulin-positive and -negative islets and the percentage of islets with insulitis in insulin-positive and -negative islets in non-diabetic and diabetic cases.","https://link.springer.com/article/10.1007%2Fs00125-015-3519-6#Tab3"
"PMID25687234","Reddy et al. (2015)","InsNeg.CD45.cells.periislet","cell",,0,"Yes",1,"NA","NA","NA",,"MP:0004031","insulitis","Mean number of peri-islet leucocytes (CD45+) per insulin-negative islet","count",,"1","1",,"NA",,"immunostaining",,,,,"Table 3: Mean number of peri- and intra-islet leucocytes and the sum of the two in relation to insulin-positive and -negative islets and the percentage of islets with insulitis in insulin-positive and -negative islets in non-diabetic and diabetic cases.","https://link.springer.com/article/10.1007%2Fs00125-015-3519-6#Tab3"
"PMID25687234","Reddy et al. (2015)","InsPos.CD45.cells.intraislet","cell",,0,"Yes",1,"NA","NA","NA",,"MP:0004031","insulitis","Mean number of intra-islet leucocytes (CD45+) per insulin-positive islet","count",,"1","1",,"NA",,"immunostaining",,,,,"Table 3: Mean number of peri- and intra-islet leucocytes and the sum of the two in relation to insulin-positive and -negative islets and the percentage of islets with insulitis in insulin-positive and -negative islets in non-diabetic and diabetic cases.","https://link.springer.com/article/10.1007%2Fs00125-015-3519-6#Tab3"
"PMID25687234","Reddy et al. (2015)","InsNeg.CD45.cells.intraislet","cell",,0,,1,"NA","NA","NA",,"MP:0004031","insulitis","Mean number of intra-islet leucocytes (CD45+) per insulin-negative islet",,,,,,,,,,,,,"Table 3: Mean number of peri- and intra-islet leucocytes and the sum of the two in relation to insulin-positive and -negative islets and the percentage of islets with insulitis in insulin-positive and -negative islets in non-diabetic and diabetic cases.","https://link.springer.com/article/10.1007%2Fs00125-015-3519-6#Tab3"
"PMID25687234","Reddy et al. (2015)","InsPos.CD45.prct","cell",,0,,1,"NA","NA","NA",,"MP:0004031","insulitis","Percent of insulin-positive islets with insulitis (with CD45+ infiltrates)","%",,,,,,,,,,,,"Table 3: Mean number of peri- and intra-islet leucocytes and the sum of the two in relation to insulin-positive and -negative islets and the percentage of islets with insulitis in insulin-positive and -negative islets in non-diabetic and diabetic cases.","https://link.springer.com/article/10.1007%2Fs00125-015-3519-6#Tab3"
"PMID25687234","Reddy et al. (2015)","InsNeg.CD45.prct","cell",,0,,1,"NA","NA","NA",,"MP:0004031","insulitis","Percent of insulin-negative islets with insulitis (with CD45+ infiltrates)","%",,,,,,,,,,,,"Table 3: Mean number of peri- and intra-islet leucocytes and the sum of the two in relation to insulin-positive and -negative islets and the percentage of islets with insulitis in insulin-positive and -negative islets in non-diabetic and diabetic cases.","https://link.springer.com/article/10.1007%2Fs00125-015-3519-6#Tab3"
"PMID25687234","Reddy et al. (2015)","CD45.prct","cell",,0,,1,"NA","NA","NA",,"MP:0004031","insulitis","Percent of islets with insulitis (with CD45+ infiltrates)","%",,,,,,,,,,,,"Table 3: Mean number of peri- and intra-islet leucocytes and the sum of the two in relation to insulin-positive and -negative islets and the percentage of islets with insulitis in insulin-positive and -negative islets in non-diabetic and diabetic cases.","https://link.springer.com/article/10.1007%2Fs00125-015-3519-6#Tab3"
"PMID25576800","Harms et al. (2015)","IL18.cells","cell",,0,"Contact authors",0,"NA","NA","NA",,,,"Percentage of islets with at least two IL-18+ cells, quantitated in 25 islets per sample","%",,"1","1",,"0-100",,"immunostaining",,"interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315765/figure/F5/"
"PMID25576800","Harms et al. (2015)","IL18.cells.high","cell",,0,"Contact authors",0,"NA","NA","NA",,,,"Percentage of islets with at least five IL-18+ cells, quantitated in 25 islets per sample","%",,"1","1",,"0-100",,"immunostaining",,"interval",,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315765/figure/F5/"
"PMID25532042","Grzesik et al. (2014)","x12LO","protein",,0,"Yes",1,"239","NA","NA",,,,"Staining for 12LO (positive or negative)","[Positive,Negative]",,"1","1",,"0-1",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333045/figure/F2/"
"PMID25532042","Grzesik et al. (2014)","islet.area","tissue","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,"MP:0009166","abnormal pancreatic islet number","Islet area as % of pancreas area","%",,"1","1",,"0-100",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333045/figure/F2/"
"PMID25532042","Grzesik et al. (2014)","beta.area","cell","type B pancreatic cell",0,"Contact authors",0,"NA","NA","NA",,"MP:0020578","abnormal pancreatic beta cell number","Beta cells as % of islet area","%",,"1","1",,"0-100",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333045/figure/F2/"
"PMID25532042","Grzesik et al. (2014)","x12LO.pancreas","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"Expression of 12LO as % of pancreas area","%",,"1","1",,"0-100",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333045/figure/F2/"
"PMID25532042","Grzesik et al. (2014)","x12LO.islet","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"Expression of 12LO as % of islet area","%",,"1","1",,"0-100",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333045/figure/F2/"
"PMID25532042","Grzesik et al. (2014)","x12LO.beta","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"Expression of 12LO as % of beta cell area (insulin-positive area)","%",,"1","1",,"0-100",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333045/figure/F2/"
"PMID25422108","Krogvold et al. (2014)","VP1","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"Enterovirus VP1 expression (positive or negative). See note.","[Positive,Negative]","Viral","1","1",,"0-1",,"immunostaining",,,,"Included only nondiabetic organ donors from nPOD, used as controls for DiVid cohort. All samples tested negative for VP1.",,"NA"
"PMID25226365","Subauste et al. (2014)","beta.mass","cell","type B pancreatic cell",0,"Contact authors",0,"NA","NA","NA",,,,"Estimated beta cell mass","grams",,"1","1",,"NA",,"immunostaining","Insulin stained area was quantified with ImageProplus (Media Cybernetics, Rockville, MD) and expressed as ratio to the total pancreatic area. The average ratio between insulin stained area and total areas was multiplied by the pancreatic weight in gms thus yielding the estimated BCM in gms.",,,,,"NA"
"PMID25077543","Piran et al. (2014)","delta2alpha","cell","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Delta to alpha cell ratio","somatostatin+ area/glucagon+ area",,"1","1",,"NA",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123101/figure/fig6/"
"PMID24947367","Rodriguez-Calvo et al. (2014)","CD8.cells","cell","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,"MP:0004031","insulitis","Mean CD8+ cell infiltration reported as mean density values","CD8+ cells/mm^2",,"1","1",,"NA",,"immunostaining","An average of 10 to 15 stained images (surface area of 1.215 mm2) from each tissue section acquired and analysis was performed using a custom macro developed in MATLAB and ImageJ. islet regions were identified as contiguous areas of insulin or glucagon staining at or above a threshold intensity value. CD8+ cells were identified as areas of CD8 staining using optimized and identical threshold values for intensity and size for all the images. A comparison between manual counts and software-assisted counts was performed in 15 images in order to validate the macro used to quantify CD8+ cells.",,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207385/bin/supp_db14-0549_DB140549SupplementaryData.pdf"
"PMID24947367","Rodriguez-Calvo et al. (2014)","CD4.cells","cell","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,"MP:0004031","insulitis","Mean CD4+ cell infiltration reported as mean density values","CD4+ cells/mm^2",,"1","1",,"NA",,"immunostaining","For CD4 five images from each donor were analyzed manually.",,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207385/bin/supp_db14-0549_DB140549SupplementaryData.pdf"
"PMID24947367","Rodriguez-Calvo et al. (2014)","CD11c.cells","cell","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Mean immune cell infiltration reported as mean density values","CD11c+ cells/mm^2",,"1","1",,"NA",,"immunostaining","For CD11c five images from each donor were analyzed manually.",,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207385/bin/supp_db14-0549_DB140549SupplementaryData.pdf"
"PMID24939426","Arif et al. (2014)","CD20.cat","cell","islet of Langerhans",0,"Yes",1,"NA","NA","NA",,"MP:0004031","insulitis","Mean CD20+ cells (cells stained per islet) and categorized into CD20Hi or CD20Lo; only in islets with residual immune staining for insulin","[Lo,Hi]",,"1","1",,"0-1",,"immunostaining","CD20 staining was used to subdivide 21 patients into CD20Hi and CD20Lo categories by using mean CD20+ cell counts above (CD20Hi) and below (CD20Lo) 3.7 cells/islet.",,,,"Figure 4: Immunohistological analysis of pancreas from patients with type 1 diabetes reveals heterogeneity of insulitis. ","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207393/figure/F4/"
"PMID24939426","Arif et al. (2014)","CD8.cells","cell","islet of Langerhans",0,"Contact authors",1,"NA","NA","NA",,,,"Mean CD8+ cells (cells stained per islet); only in islets with residual immune staining for insulin","cells/islet",,,,,,,,,,,,,
"PMID24939426","Arif et al. (2014)","CD68.cells","cell","islet of Langerhans",0,"Contact authors",1,"NA","NA","NA",,,,"Mean CD68+ cells (cells stained per islet); only in islets with residual immune staining for insulin","cells/islet",,,,,,,,,,,,,
"PMID24939426","Arif et al. (2014)","CD4.cells","cell","islet of Langerhans",0,"Contact authors",1,"NA","NA","NA",,,,"Mean CD4+ cells (cells stained per islet); only in islets with residual immune staining for insulin","cells/islet",,,,,,,,,,,,,
"PMID24677718","Bogdani et al. (2014)","Hyaluronan.islet","protein","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Hyaluronan-positive area in peri- and intra-islet ","HA+ area/mm^2",,"NA","1",,"NA",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113060/figure/F2/"
"PMID24677718","Bogdani et al. (2014)","Hyaluronan.follicle","protein","lymph node follicle",0,"Contact authors",0,"NA","NA","NA",,,,"Hyaluronan-positive area in B cell follicles","%",,"NA","1",,"0-100",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113060/figure/F6/"
"PMID24677718","Bogdani et al. (2014)","Hyaluronan.spleen","protein","spleen",0,"Contact authors",0,"NA","NA","NA",,,,"Hyaluronan-positive area in splenic T cell area","%",,"NA","1",,"0-100",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113060/figure/F6/"
"PMID24677718","Bogdani et al. (2014)","Hyaluronan.PLN","protein","pancreatic lymph node",0,"Contact authors",0,"NA","NA","NA",,,,"Hyaluronan-positive area in pancreatic lymph node (PLN) tissue area ",,,"NA","1",,,,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113060/figure/F6/"
"PMID24677718","Bogdani et al. (2014)","IalphaI","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"HA-binding protein",,,,,,,,"immunostaining",,,,,,"NA"
"PMID24677718","Bogdani et al. (2014)","Versican","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"HA-binding protein",,,,,,,,"immunostaining",,,,,,"NA"
"PMID24677718","Bogdani et al. (2014)","TSG6","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"HA-binding protein",,,,,,,,"immunostaining",,,,,,"NA"
"PMID24498006","Ye et al. (2014)","Mmc.cells","cell","pancreas",0,"Yes",1,"NA","NA","NA",,,,"Maternal microchimeric cell quantification in pancreas","total no. MMc/total cells (%)",,,"1",,,,"immunostaining",,,,,"Table 2: Frequencies of MMc in T1D and control male human pancreases.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909047/table/pone-0086985-t002/"
"PMID24498006","Ye et al. (2014)","Ins.Mmc.cells","cell","type B pancreatic cell",0,"Yes",1,"NA","NA","NA",,,,"Enrichment of MMcs in the beta cell fraction","no. of insulin+ MMc/total cells (%)",,,"1",,,,"immunostaining",,,,,"Table 2: Frequencies of MMc in T1D and control male human pancreases.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909047/table/pone-0086985-t002/"
"PMID24264405","Yip et al. (2013)","Adora1","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"Expression of adenosine A1 receptor (Adora1) by staining; no quantification",,,,,,,,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837064/figure/F3/"
"PMID24264405","Yip et al. (2013)","ADORA1.var","genotype",,0,"Yes",1,"134","NA","NA",,,,"Presence of a Adora1 variant assessed by RT-PCR",,,,,,,,"immunostaining",,,,,"Fig 4: An alternatively spliced isoform of Adora1 is expressed in the pancreas of NOD and AA+ patients.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837064/figure/F4/"
"PMID23920110","Kavishwar et al. (2013)","sphingo.cat","protein",,0,"Yes",1,"NA","NA","NA",,"MP:0009823","abnormal sphingomyelin level","Quantification of sphingomyelin (SM) patches as IC2-antibody staining intensity","staining intensity score",,,,,"0-4",,"immunostaining",,,,,"Table 1","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840740/table/table1-0022155413502792/"
"PMID23920110","Kavishwar et al. (2013)","Ins.cat","protein",,0,"Yes",1,"NA","NA","NA",,,,"Staining for Insulin","staining intensity score",,,,,"0-5",,,,,,,"Table 1","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840740/table/table1-0022155413502792/"
"PMID23920110","Kavishwar et al. (2013)","Gcg.cat","protein",,0,"Yes",1,"NA","NA","NA",,,,"Staining for Glucagon","staining intensity score",,,,,"0-5",,,,,,,"Table 1","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840740/table/table1-0022155413502792/"
"PMID23904478","Chen et al. (2013)","IL15","transcript",,0,"Individual-level data not available",-1,"NA","NA","NA",,,,"Expression of IL-15 mRNA reported as normalized counts to three housekeeping genes",,,"0","1",,,,"immunostaining",,,,"Individual-level data is not available.",,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3746870/figure/fig06/"
"PMID23904478","Chen et al. (2013)","IL15Ra","transcript",,0,"Individual-level data not available",-1,"NA","NA","NA",,,,"Expression of IL-15Ralpha reported as normalized counts to three housekeeping genes",,,"0","1",,,,"immunostaining",,,,"Individual-level data is not available.",,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3746870/figure/fig06/"
"PMID23904478","Chen et al. (2013)","MxA","protein",,0,"Yes",1,"4599","NA","NA",,,,"Expression of MxA (a GTPase induced by type 1 IFN) detected by staining","[Positive,Negative]",,"0","1",,"0-1",,"immunostaining",,,"In text: Immunohistochemistry demonstrated IL-15 expression in the islets in all T1D patients examined (four out of four, nPOD-6038, nPOD-6046, nPOD-6050, and nPOD-6084), whereas IL-15 was detected only in the pancreatic islets in one out of four normal donors and two out of five autoantibody positive donors (Fig. 6A). Interestingly, in two cases where IL-15 was positive, we also detected islet expression of MxA, a GTPase induced by type 1 IFN (?/?), that has been reported to interfere with virus multiplication and spread (28) (Fig. S6).","Data values are mentioned in publication text.","Fig S6: Increased expression of MxA in the islets of a patient with type 1 diabetes [Network for Pancreatic Organ Donors (nPOD)-6084] and an autoantibody
positive donor (nPOD-6023).","http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1312911110/-/DCSupplemental/pnas.201312911SI.pdf?targetid=nameddest=SF6"
"PMID23139348","Korpos et al. (2012)","BM.cat","tissue",,0,"Yes",1,"NA","NA","NA",,"MP:0004272","abnormal basement membrane morphology","Analysis of extracellular matrix (ECM) composition based on staining for basement membrane (BM) components; pan-laminin, collagen, perlecan, agrin, nidogen1/2",,,"1","1",,"NA","1 = intact; 0 = no staining in some areas","immunostaining",,"ordinal",,,"Supplementary Table 2: Summary of analyzed nPOD samples.","http://diabetes.diabetesjournals.org/highwire/filestream/72250/field_highwire_adjunct_files/0/DB120432SupplementaryData.pdf"
"PMID23139348","Korpos et al. (2012)","IM.cat","tissue",,0,"Yes",1,"NA","NA","NA",,"MP:0013258","abnormal extracellular matrix morphology","Analysis of extracellular matrix (ECM) composition based on staining for interstitial matrix (IM) components; collagen, fibronectin, tenascin-C, matrillin, fibrillin",,,"0","0",,"NA","1 = intact; 0 = no staining in some areas","immunostaining",,"ordinal",,,"Supplementary Table 2: Summary of analyzed nPOD samples.","http://diabetes.diabetesjournals.org/highwire/filestream/72250/field_highwire_adjunct_files/0/DB120432SupplementaryData.pdf"
"PMID23064357","Richardson et al. (2012)","VP1","protein",,0,"Yes",1,"NA","NA","NA",,"MP:0020163","increased susceptibility to virus induced diabetes","Enterovirus VP1 expression as # Insulin-containing islets (ICIs) with multiple VP1+ cells","Count","Viral","1","1",,,,"immunohistochemistry",,,,,"Table 1: nPOD type 1 diabetes patients and non-diabetic controls.","https://link.springer.com/article/10.1007%2Fs00125-012-2745-4#Tab1"
"PMID23064357","Richardson et al. (2012)","ICI","cell",,0,"Yes",1,"NA","NA","NA",,"MP:0020578","abnormal pancreatic beta cell number","Count of insulin-containing islets","Count",,,,,,,,,,,,"Table 1: nPOD type 1 diabetes patients and non-diabetic controls.","https://link.springer.com/article/10.1007%2Fs00125-012-2745-4#Tab1"
"PMID23064357","Richardson et al. (2012)","VP1.ICI","phenotype",,0,"Yes",1,"NA","NA","NA",,"MP:0020163","increased susceptibility to virus induced diabetes","Enterovirus VP1 expression as percent of insulin-containing islets with multiple VP1+ cells (VP1/ICI)","%","Viral",,,,,,,,,,"This is a derived feature. See VP1 and ICI.","Table 1: nPOD type 1 diabetes patients and non-diabetic controls.","https://link.springer.com/article/10.1007%2Fs00125-012-2745-4#Tab1"
"PMID22923498","Yip et al. (2012)","EIF4G3","transcript",,0,"Contact authors",0,"NA","NA","NA",,,,"EIF4G3 mRNA expression","expression relative to housekeeping gene (beta-actin) x10E-6",,"0","1",,"NA",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604916/figure/MJS052F2/"
"PMID22923498","Yip et al. (2012)","EIF4G1","transcript",,0,"Contact authors",0,"NA","NA","NA",,,,"EIF4G1 mRNA expression","expression relative to housekeeping gene (GAPDH) x10E-3",,"0","0",,"NA",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604916/figure/MJS052F2/"
"PMID22745242","Gregg et al. (2012)","islet.diameter","tissue","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Average islet diameter","micrometer (uM)",,"NA","NA",,"NA",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431572/bin/supp_jc.2012-1206_12-1206_supp_data.pdf"
"PMID22745242","Gregg et al. (2012)","beta2alpha","cell","type B pancreatic cell|pancreatic A cell",0,"Contact authors",0,"NA","NA","NA",,,,"Beta cell to alpha cell ratio","ratio",,"NA","NA",,"NA",,"immunostaining","The numbers of insulin-positive beta-cells and glucagon-positive a-cells were counted and the islet b-cell to a-cell ratio calculated, with at least 10 islets analyzed per section.",,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431572/figure/F1/"
"PMID22745242","Gregg et al. (2012)","beta2delta","cell","type B pancreatic cell|pancreatic ductal cell",0,"Contact authors",0,"NA","NA","NA",,,,"Beta cell to delta cell ratio","ratio",,"NA","NA",,"NA",,"immunostaining","The numbers of insulin-positive b-cells and somatostatin-positive d-cells were counted and the islet b-cell to d-cell ratio calculated, with at least 10 islets analyzed per section.",,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431572/figure/F2/"
"PMID22745242","Gregg et al. (2012)","prox.neurons","cell","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"Distance of a Tuj1-positive neuron from an islet cluster","micrometer (uM)",,"NA","NA",,"NA",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431572/figure/F3/"
"PMID22745242","Gregg et al. (2012)","CK19.Ins.duct","cell","type B pancreatic cell",0,"Contact authors",0,"NA","NA","NA",,,,"Beta cell neogenesis from ductal cells reported as percentage insulin+/CK-19+ cells and insulin+ cells associated in pancreatic ducts","% Ins+/CK-19+ cells and insulin+ cells associated in pancreatic ducts",,"NA","NA",,"0-100",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431572/figure/F4/"
"PMID22745242","Gregg et al. (2012)","Ki67.Ins","cell","type B pancreatic cell",0,"Contact authors",0,"NA","NA","NA",,,,"Beta cell proliferation measured as insulin+/Ki67+ cells as a percentage of all insulin-positive cells in each section","% Ins+ cells",,"NA","NA",,"0-100",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431572/figure/F5/"
"PMID22745242","Gregg et al. (2012)","CK19.Ins","cell","pancreatic ductal cell",0,"Contact authors",0,"NA","NA","NA",,,,"Ductal cell proliferation measured as CK-19+/Ki67+ cells as a percentage of all CK-19-positive cells in each section","% CK-19+ cells",,"NA","NA",,"0-100",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431572/figure/F6/"
"PMID22699564","Marhfour et al. (2012)","CHOP","protein","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"CHOP immunostaining intensity",,"ER",,,,"NA",,"immunostaining",,,,,,"https://media.springernature.com/original/springer-static/image/art%3A10.1007%2Fs00125-012-2604-3/MediaObjects/125_2012_2604_Fig2_HTML.gif"
"PMID22699564","Marhfour et al. (2012)","BIP","protein","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"BIP immunostaining intensity",,"ER",,,,"NA",,"immunostaining",,,,,,"https://media.springernature.com/original/springer-static/image/art%3A10.1007%2Fs00125-012-2604-3/MediaObjects/125_2012_2604_Fig2_HTML.gif"
"PMID22699564","Marhfour et al. (2012)","XBP1","protein","islet of Langerhans",0,"Contact authors",0,"NA","NA","NA",,,,"XBP-1 immunostaining intensity",,"ER",,,,"NA",,"immunostaining",,,,,,"https://media.springernature.com/original/springer-static/image/art%3A10.1007%2Fs00125-012-2604-3/MediaObjects/125_2012_2604_Fig2_HTML.gif"
"PMID22213807","Coppieters et al. (2012)","Ins.cat","protein",,0,"Yes",1,"NA","NA","NA",,"MP:0009255","degranulated pancreatic beta cells","Insulin expression, category","[Normal,Decreased,Negative]",,"1","1",,"0-2","insulin: ++, normal numbers of insulin-sufficient islets, in excess of 50 per section; +, decreased numbers (<50; average insulin + islet size reduced);  -, negative","immunostaining",,"ordinal",,,"Table S1: Insulin, CD8, and HLA Class I expression patterns within pancreatic islets from diabetic individuals and controls","http://jem.rupress.org/highwire/filestream/102893/field_highwire_adjunct_files/0/JEM_20111187_sm.pdf"
"PMID22213807","Coppieters et al. (2012)","MHCI.cat","protein",,0,"Yes",1,"NA","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","MHC Class I expression, category","[Negative,Positive]",,"0","0",,"0-1","MHC I: -, negative, based on nondiabetic controls, normal expression approximates three positive nonendocrine cells; +, positive.","immunostaining",,"ordinal",,,"Table S1: Insulin, CD8, and HLA Class I expression patterns within pancreatic islets from diabetic individuals and controls","http://jem.rupress.org/highwire/filestream/102893/field_highwire_adjunct_files/0/JEM_20111187_sm.pdf"
"PMID22213807","Coppieters et al. (2012)","CD8.cat","protein",,0,"Yes",1,"NA","NA","NA",,"MP:0004031","insulitis","Islet CD8 expression, category","[Normal,High]",,"0","0",,"0-1","Islet CD8: normal, less than five per islet; +, accumulation of more than five cells per islet","immunostaining","In situ tetramer staining","ordinal",,,"Table S1: Insulin, CD8, and HLA Class I expression patterns within pancreatic islets from diabetic individuals and controls","http://jem.rupress.org/highwire/filestream/102893/field_highwire_adjunct_files/0/JEM_20111187_sm.pdf"
"PMID22210319","Sarkar et al. (2012)","CCL5","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"Expression assessed through IHC","NA",,,"1",,"NA",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266427/figure/F6/"
"PMID22210319","Sarkar et al. (2012)","CCL8","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"Expression assessed through IHC","NA",,,"1",,"NA",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266427/figure/F6/"
"PMID22210319","Sarkar et al. (2012)","CXCL9","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"Expression assessed through IHC","NA",,,"1",,"NA",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266427/figure/F6/"
"PMID22210319","Sarkar et al. (2012)","CX3CL1","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"Expression assessed through IHC","NA",,,"1",,"NA",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266427/figure/F6/"
"PMID22210319","Sarkar et al. (2012)","CXCL10","protein",,0,"Contact authors",0,"NA","NA","NA",,,,"Expression assessed through IHC","NA",,,"1",,"NA",,"immunostaining",,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266427/figure/F7/"
"PMID20062967","Gianani et al. (2010)","Ins.cat","protein",,0,"Yes",1,"NA","NA","NA",,"MP:0020578","abnormal pancreatic beta cell number","Insulin+ islets","[Yes,No]",,"1","1",,"NA",,"immunostaining",,,,,"Table 1: Demographic information and characteristics as shown in the 20 childhood-onset diabetic patients analysed.","https://link.springer.com/article/10.1007%2Fs00125-009-1642-y#Tab1"
"PMID20062967","Gianani et al. (2010)","HLA.cat","protein",,0,"Yes",1,"NA","NA","NA",,"MP:0001836","abnormal antigen presentation via MHC class I","Class I HLA+ beta","[Yes,No]","HLA","1","1",,"NA",,"immunostaining",,,,,"Table 1: Demographic information and characteristics as shown in the 20 childhood-onset diabetic patients analysed.","https://link.springer.com/article/10.1007%2Fs00125-009-1642-y#Tab1"
"PMID20062967","Gianani et al. (2010)","Survivin.cat","protein",,0,"Yes",1,"332","NA","NA",,,,"Survivin+ beta","[Yes,No]",,"1","1",,"NA",,"immunostaining",,,,,"Table 1: Demographic information and characteristics as shown in the 20 childhood-onset diabetic patients analysed.","https://link.springer.com/article/10.1007%2Fs00125-009-1642-y#Tab1"
"Aab","nPODCore","GADA","phenotype",,0,"Yes",1,"NA","NA","NA",,,,,,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / AutoAb Results","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5045"
"Aab","nPODCore","IA2A","phenotype",,0,"Yes",1,"NA","NA","NA",,,,,,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / AutoAb Results","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5045"
"Aab","nPODCore","mIAA","phenotype",,0,"Yes",1,"NA","NA","NA",,,,,,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / AutoAb Results","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5045"
"Aab","nPODCore","Znt8A","phenotype",,0,"Yes",1,"NA","NA","NA",,,,,,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / AutoAb Results","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5045"
"Aab","nPODCore","AutoAb.count","phenotype",,0,"Yes",1,"NA","NA","NA",,,,,,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / AutoAb Results","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5045"
"Demographics","nPODCore","age","phenotype",,0,"Yes",1,"NA","NA","NA",,,,,,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / Demographics","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5001"
"Demographics","nPODCore","gender","phenotype",,0,"Yes",1,"NA","NA","NA",,,,,,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / Demographics","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5001"
"Demographics","nPODCore","ethnic.grp","phenotype",,0,"Yes",1,"NA","NA","NA",,,,,,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / Demographics","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5001"
"Demographics","nPODCore","cause.death.cat","phenotype",,0,"Yes",1,"NA","NA","NA",,,,,,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / Demographics","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5001"
"Demographics","nPODCore","height","phenotype",,0,"Yes",1,"NA","NA","NA",,,,,,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / Demographics","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5001"
"Demographics","nPODCore","weight","phenotype",,0,"Yes",1,"NA","NA","NA",,,,,,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / Demographics","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5001"
"Demographics","nPODCore","BMI","phenotype",,0,"Yes",1,"NA","NA","NA",,"MP:0020182","abnormal body mass index","Body Mass Index",,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / Demographics","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5001"
"Demographics","nPODCore","ABO.grp","phenotype",,0,"Yes",1,"NA","NA","NA",,,,,,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / Demographics","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5001"
"DiabetesInfo","nPODCore","db.duration","clinical",,0,"Yes",1,"NA","NA","NA",,,,,,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / Diabetes Info","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5008"
"DiabetesInfo","nPODCore","age.onset","phenotype",,0,"Yes",1,"NA","NA","NA",,,,,,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / Diabetes Info","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5008"
"DiabetesInfo","nPODCore","Cpeptide","phenotype",,0,"Yes",1,"NA","NA","NA",,"MP:0003564","abnormal insulin secretion","C-peptide",,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / Diabetes Info","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5008"
"DiabetesInfo","nPODCore","HbA1c","phenotype",,0,"Yes",1,"NA","NA","NA",,"MP:0000188","abnormal circulating glucose level","HbA1c",,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / Diabetes Info","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5008"
"DiabetesInfo","nPODCore","peak.gluc","phenotype",,0,"Yes",1,"NA","NA","NA",,"MP:0002078","abnormal glucose homeostasis","Peak glucose",,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / Diabetes Info","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5008"
"DiabetesInfo","nPODCore","donor.type","phenotype",,0,"Yes",1,"NA","NA","NA",,,,,,,,,,,,,,,,"An investigator account is required for accessing data.","nPOD DataShare / Diabetes Info","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5008"
"Histopathology","nPODCore","Ins","phenotype","pancreas",0,"Yes",1,"NA","NA","NA",,"MP:0020578","abnormal pancreatic beta cell number",,,,,,,,,,,,,"An investigator account is required for accessing data. This is a derived feature, i.e. extracted from text reports.","nPOD DataShare / Histopathology","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5011"
"Histopathology","nPODCore","amyloid","phenotype","pancreas",0,"Yes",1,"NA","NA","NA",,"MP:0000604","amyloidosis",,,,,,,,,,,,,"An investigator account is required for accessing data. This is a derived feature, i.e. extracted from text reports.","nPOD DataShare / Histopathology","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5011"
"Histopathology","nPODCore","dysplasia","phenotype","pancreas",0,"Yes",1,"NA","NA","NA",,"MP:0001944","abnormal pancreas morphology",,,,,,,,,,,,,"An investigator account is required for accessing data. This is a derived feature, i.e. extracted from text reports.","nPOD DataShare / Histopathology","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5011"
"Histopathology","nPODCore","metaplasia","phenotype","pancreas",0,"Yes",1,"NA","NA","NA",,"MP:0013221","pancreatic acinar-to-ductal metaplasia",,,,,,,,,,,,,"An investigator account is required for accessing data. This is a derived feature, i.e. extracted from text reports.","nPOD DataShare / Histopathology","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5011"
"Histopathology","nPODCore","pancreatitis","phenotype","pancreas",0,"Yes",1,"NA","NA","NA",,"MP:0001869","pancreas inflammation",,,,,,,,,,,,,"An investigator account is required for accessing data. This is a derived feature, i.e. extracted from text reports.","nPOD DataShare / Histopathology","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5011"
"Histopathology","nPODCore","atrophy","phenotype","pancreas",0,"Yes",1,"NA","NA","NA",,"MP:0009164","exocrine pancreas atrophy",,,,,,,,,,,,,"An investigator account is required for accessing data. This is a derived feature, i.e. extracted from text reports.","nPOD DataShare / Histopathology","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5011"
"Histopathology","nPODCore","fibrosis","phenotype","pancreas",0,"Yes",1,"NA","NA","NA",,"MP:0003334","pancreas fibrosis",,,,,,,,,,,,,"An investigator account is required for accessing data. This is a derived feature, i.e. extracted from text reports.","nPOD DataShare / Histopathology","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5011"
"Histopathology","nPODCore","CD3","phenotype","pancreas",0,"Yes",1,"NA","NA","NA",,"MP:0004031","insulitis",,,,,,,,,,,,,"An investigator account is required for accessing data. This is a derived feature, i.e. extracted from text reports.","nPOD DataShare / Histopathology","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5011"
"Histopathology","nPODCore","Ki67","phenotype","pancreas",0,"Yes",1,"NA","NA","NA",,"MP:0005518","abnormal pancreas regeneration",,,,,,,,,,,,,"An investigator account is required for accessing data. This is a derived feature, i.e. extracted from text reports.","nPOD DataShare / Histopathology","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5011"
"Histopathology","nPODCore","islet.freq","phenotype","pancreas",0,"Yes",1,"NA","NA","NA",,"MP:0009166","abnormal pancreatic islet number",,,,,,,,,,,,,"An investigator account is required for accessing data. This is a derived feature, i.e. extracted from text reports.","nPOD DataShare / Histopathology","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5011"
"Histopathology","nPODCore","islet.size","phenotype","pancreas",0,"Yes",1,"NA","NA","NA",,"MP:0009170","abnormal pancreatic islet size",,,,,,,,,,,,,"An investigator account is required for accessing data. This is a derived feature, i.e. extracted from text reports.","nPOD DataShare / Histopathology","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5011"
"HLA","nPODCore","HLA","genotype",,0,"Yes",1,"NA","NA","NA",,,,,,,,,,,,,,,,"An investigator account is required for accessing data. This is a derived feature, i.e. extracted from text reports.","nPOD DataShare / Hi-Res HLA","https://npoddatashare.coh.org/labkey/study/nPOD%20DataShare/dataset.view?datasetId=5029"
"GSE72492","Yip et al. (unpublished)","Transcriptomics","transcript","pancreas",1,"Yes",1,"NA","NA","NA",,,,,,,,,,,,"microarray",,,,,"Gene expression in the pancreas of healthy control, auto-antibody positive, and type 1 diabetic subjects","https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72492"
